

## CURRICULUM VITAE

**Daniel Benjamin Mark**

**Office Address:** Duke Clinical Research Institute  
PO Box 17969  
Durham, North Carolina 27715  
(919) 668-8775  
FAX: (919) 668-7060  
daniel.mark@duke.edu

### Education:

Hampshire College	B.A. 1974
Tufts University School of Medicine	M.D. 1978
Harvard School of Public Health	M.P.H. 1979

### Training:

Internship in Internal Medicine	7/79 - 6/80	University of Virginia Hospital
Residency in Internal Medicine	7/80 - 6/82	University of Virginia Hospital
Fellowship in Cardiology	7/82 - 6/85	Duke University Medical Center

### Diplomate American Board of Internal Medicine

Specialty, Internal Medicine	09/15/82
Subspecialty, Cardiology	11/20/85

### Diplomate National Board of Medical Examiners

Certificate No 199976	07/01/1980
-----------------------	------------

### Medical Licensure:

North Carolina	#26308
Massachusetts	#48121

### Honor Societies & Awards:

AOA junior year Tufts Medical School

Research Excellence Award, Association for Pharmacoeconomics and Outcomes Research, 1997

American Society for Clinical Investigation, 1998

Association of American Physicians, 2002

Distinguished Scientist Award, American College of Cardiology, 2009

2015 Excellence in Professionalism Award, Duke University, 2015

**Other Recognition:**

The Best Doctors in America, 2002-2017

The Best Doctors in North Carolina, 2004-2017

**Academic Appointments:**

Professor of Medicine (with Tenure)	6/98 – present	Duke University Medical Center
Associate Professor of Medicine (with Tenure)	1/93 – 5/98	Duke University Medical Center
Assistant Professor of Medicine	1/87 – 12/92	Duke University Medical Center
Associate in Medicine (Cardiology)	7/85 – 12/86	Duke University Medical Center

**Professional Experience:**

Duke University Medical Center

*Current*

Director, Outcomes Research Duke Clinical Research Institute	1994 – present
Program Director, Postdoctoral Training in Cardiovascular Clinical Research T32 Program	2002 – present
Vice Chief for Academic Affairs, Cardiology Division	2010 – present
Duke Appointments, Promotions, & Tenure Committee	2010 – present

*Past*

Vice Chief, Cardiology Division	2007 – 2010
Duke Prospective Health Advisory Committee	2007 – 2012

Senior Fellow in Clinical Health Policy Duke Center for Clinical Health Policy Research	2008 – 2012
Duke Scholars Selection Committee	2006 – 2010
Vice Chancellor for Academic Affairs Search Committee	1997 – 1998
Department of Medicine Representative, Duke Institutional Review Board	1991 – 1999
Department of Medicine Representative, Duke Institutional Review Board Task Force	5/99 - 12/99
Director, Economics and Quality of Life (EQOL) Studies Research Group, Division of Cardiology	1989 – 1994
Associate Director, Section of Clinical Epidemiology and Biostatistics	1985 – 1994
Duke University Heart Center Operations Committee	1987 - 1991
Chairman, Safety and Data Monitoring Committee, Interventional Cardiology Program	1987 - 1992
Quality Assurance Committee, Division of Cardiology, Cardiac Care Unit Subdivision	1988 - 1992

#### Duke University Fuqua School of Business

Faculty Member, Health Sector Management Program	2000-2012
--	-----------

#### U.S. Food and Drug Administration

Special Assignment to Center for Devices and Radiologic Health	2016-2017
--	-----------

#### National Committees

##### **American College of Cardiology**

Database Research and Development Committee (1998-2002)

Outcomes Assessment Subcommittee (1998-2002)

Member, ACC Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) (2000-2001)

Bethesda Conference #33, Task Force 2 Steering Committee: The cost of prevention: can we afford it, can we afford not to do it? (2001-2002)

Bethesda Conference #34, Task Force 5 Steering Committee, Chair: Can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? (2001-2002)

Chair, Writing Committee, ACCF/ACR/AHA/ASNC/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary CT Angiography (2009)

Member, Writing Committee, Appropriate Use Criteria for Cardiac Computed Tomography (2010)

Chair, Writing Committee, ACCF/ACP/AHA/ASE/ASNC/HRS/IAC/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNM 2012 Health Policy Statement on Use of Cardiovascular Diagnostic Imaging (2011-2012)

Member, Writing Committee, ACCF/AHA Cost Considerations into the Development of Guidelines and Performance Measures Methodology (2012-2014)

#### **American Heart Association**

Research Program and Evaluation Committee (1999-2002)

Quality of Care and Outcomes Research Interdisciplinary Working Group (2000-2002)

Research Committee (2002-2003)

Council on Epidemiology and Prevention, Leadership Committee (2003-2004)

Member, Writing Committee, AHA Scientific Statement on Education and Psychological Interventions to Improve Outcomes for ICD Recipients and Their Families (2010-2012)

#### **National Institutes of Health**

National Heart, Lung, and Blood Advisory Committee

Working Group on Clinical Trials (2015-present)

#### International Committees

Advisory Board Member, Brazilian Clinical Research Institute, Sao Paulo Brazil (2010-present)

#### Research Grant Review

Department of Veterans Affairs

Cooperative Studies Evaluation Committee (1997-2000)

National Institutes of Health, Epidemiology  
and Disease Control 2 Study Section (ad hoc member)

National Institutes of Health, Clinical  
Trials Review Study Section (ad hoc member)

Agency for Health Care Policy and Research

Veterans Administration Medical Research Service

American Heart Association, Behavioral Science  
Epidemiology & Prevention Study Committee

Medical Research Council, Canada

National Institutes of Health, National Heart, Lung, and Blood Institute.  
Clinical Trials Review Committee (2014 – 2017)

#### National Practice Guidelines

AHCPR-NIH Unstable Angina Guideline (1994)

American College of Cardiology Coronary Stent Consensus Guideline (1996)

American College of Cardiology Exercise Testing Guideline (1997)

ACC/AHA Guidelines for Exercise Testing (2001)

American College of Chest Physicians Evidence Based Guidelines on Antithrombotic and  
Thrombolytic Therapy (2008)

#### Editor-in-Chief

American Heart Journal (2015–present)

#### Editor

American Heart Journal (1996–2015)

#### Editorial Boards

Alternative Therapies in Health and Medicine, Associate Editor (2000–2001)

Psychosomatic Medicine, Editorial Board (2002–present)

Journal of Cardiopulmonary Rehabilitation, Editorial Board (2003–present)

Journal of Alternative and Complementary Medicine, Associate Section Editor (2004–  
2006)

#### Journal Review (1984–present)

New England Journal of Medicine

Journal of the American Medical Association

Lancet

Circulation  
European Heart Journal  
Heart  
Annals of Internal Medicine  
Journal of the American College of Cardiology  
JAMA Cardiology  
Health Affairs  
Medical Care  
Journal of Thoracic and Cardiovascular Surgery  
American Journal of Cardiology  
American Journal of Medicine  
Journal of General Internal Medicine  
Journal of Clinical Epidemiology  
Health Services Research  
Pharmacoeconomics  
Journal of Cardiac Rehabilitation  
Journal of Electrocardiology  
Archives of Internal Medicine  
International Journal of Cardiology  
Medical Decision Making  
Psychosomatic Medicine  
Neurology  
Health Psychology  
Journal of Cardiopulmonary Rehabilitation  
European Journal of Health Economics

**Hospital Appointments:**

Duke University Medical Center

Vice Chief for Academic Affairs Cardiology Division	2010-present
Vice Chief, Cardiology Division	7/2007-2010
Co-Director Cardiac Care Unit	7/1987–present
Attending Physician Cardiac Care Unit	7/1985–present
Medical Control Officer Duke LifeFlight Transport Service	7/1990–present
Attending Physician Cardiology Consult Service	7/1985–2006

Director 7/2001–2006  
Cardiology Consult Service

Durham Veterans Administration Hospital

Acting Director 7/1985–12/1985  
Cardiac Care Unit

**Professional Societies:**

American College of Cardiology (Fellow)  
American College of Physicians (Fellow)  
American Heart Association, Council on Clinical Cardiology (Fellow)  
European Society of Cardiology (Fellow)  
American Society for Clinical Investigation  
Association of American Physicians

**Current Positions:**

Duke University Medical Center  
Professor of Medicine  
Vice Chief for Academic Affairs, Cardiology Division

Duke Clinical Research Institute  
Director, Outcomes Research

**BIBLIOGRAPHY**

**PEER-REVIEWED ARTICLES:**

1. Mark DB, Califf RM, Morris KG, Harrell FE Jr., Pryor DB, Hlatky MA, Lee KL, Rosati RA. Clinical characteristics and long-term survival of patients with variant angina. *Circulation* 1984;69:880-888.
2. Hlatky MA, Pryor DB, Harrell FE Jr., Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography: multivariable analysis. *Am J Med* 1984;77:64-71.
3. Hlatky MA, Lee KL, Harrell FE Jr., Califf RM, Pryor DB, Mark DB, Rosati RA. Tying clinical research to patient care by use of an observational database. *Statistics in Medicine* 1984;3:375-384.
4. Califf RM, Hlatky MA, Mark DB, Lee KL, Harrell FE Jr., Rosati RA, Pryor DB. Randomized trials of coronary artery bypass surgery: impact on clinical practice at Duke University Medical Center. *Circulation* 1985;72(Suppl V):136-144.

5. Califf RM, Phillips HR III, Hindman MC, Mark DB, Lee KL, Behar VS, Johnson RA, Pryor DB, Rosati RA, Wagner GS, Harrell FE Jr. Prognostic value of a coronary artery jeopardy score. *J Am Coll Cardiol* 1985;5:1055-1063.
6. Pryor DB, Califf RM, Harrell FE Jr., Hlatky MA, Lee KL, Mark DB, Rosati RA. Clinical data bases - accomplishments and unrealized potential. *Med Care* 1985;23:623-647.
7. Mark DB, Kong Y, Whalen RE. Variant angina and spontaneous coronary artery dissection. *Am J Cardiol* 1985;56:485-486.
8. Lamas GA, Muller JE, Turi ZG, Stone PH, Rutherford JD, Jaffe AS, Raabe DS, Rude RE, Mark DB, Califf RM, Gold HK, Robertson T, Passamani ER, Braunwald E, and the MILIS Study Group. A simplified method to predict occurrence of complete heart block during acute myocardial infarction. *Am J Cardiol* 1986;57:1213-1219.
9. Hlatky MA, Haney T, Barefoot JC, Califf RM, Mark DB, Pryor DB, Williams RB. Medical, psychologic and social correlates of work disability among men with coronary artery disease. *Am J Cardiol* 1986;58:911-915.
10. Papanicolaou MN, Califf RM, Hlatky MA, McKinnis RA, Harrell FE Jr., Mark DB, McCants B, Rosati RA, Lee KL, Pryor DB. The prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. *Am J Cardiol* 1986;58:1181-1187.
11. Mark DB, Hlatky MA, Lee KL, Harrell FE Jr., Califf RM, Pryor DB. Localizing coronary artery obstructions with the exercise treadmill test. *Ann Int Med* 1987;106:53-55.
12. Pryor DB, Harrell FE Jr., Rankin JS, Lee KL, Muhlbaier LH, Oldham N, Hlatky MA, Mark DB, Reves JG, Califf RM. The changing survival benefits of coronary revascularization over time. *Circulation* 1987;76(Suppl V):13-21.
13. Hlatky MA, Mark DB, Harrell FE Jr., Lee KL, Califf RM, Pryor DB. Rethinking sensitivity and specificity. *Am J Card* 1987;59:1195-1198.
14. Mark DB, Hlatky MA, Harrell FE Jr., Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Int Med* 1987;106:793-800.
15. Stack RS, O'Connor CM, Mark DB, Hinohara T, Phillips HR, Lee MM, Ramirez NM, O'Callaghan WG, Simonton CA, Carlson EB, Morris KG, Behar VS, Kong Y, Peter RH, Califf RM. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. *Circulation* 1988;77:151-161.



16. Slater DK, Hlatky MA, Mark DB, Harrell FE Jr., Pryor DB, Califf RM. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. *Am J Cardiol* 1987;60:766-770.
17. Califf RM, Mark DB, Harrell FE Jr., Hlatky MA, Lee KL, Rosati RA, Pryor DB. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. *J Am Coll Cardiol* 1988;11:20-26.
18. Bounous EP, Califf RM, Harrell FE Jr., Hinohara T, Mark DB, Ideker RE, Selvester RH, Wagner GS. Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease. *J Am Coll Cardiol* 1988;11:35-41.
19. Worley SJ, Mark DB, Smith WM, Wolf P, Califf RM, Strauss HC, Manwaring MG, Ideker RE. Comparison of time domain and frequency domain parameters from the signal averaged electrocardiogram: A multivariable analysis. *J Am Coll Cardiol* 1988;11:1041-1051.
20. Hlatky MA, Califf RM, Harrell FE Jr., Lee KL, Mark DB, Pryor DB. Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. *J Am Coll Cardiol* 1988;11:237-45.
21. Simonton CA, Mark DB, Hinohara T, Rendall DS, Phillips HR, Peter RH, Behar VS, Kong Y, O'Callaghan WG, O'Connor C, Califf RM, Stack RS. Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. *J Am Coll Cardiol* 1988;11:698-705.
22. Stack RS, Califf RM, Hinohara T, Phillips HR, Pryor DB, Simonton CS, Carlson EB, Morris KG, Behar VS, Kong Y, Peter RH, Hlatky MA, O'Connor CM, Mark DB. Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1988;11:1141-1149.
23. Bellinger RL, Califf RM, Mark DB, Weber RA, Collins P, Stone J, Phillips, HR, German L, Stack RS. Helicopter transport of patients during acute myocardial infarction. *Am J Cardiol* 1988;61:718-722.
24. Hlatky MA, Cotugno H, O'Connor C, Mark DB, Pryor DB, Califf RM. Adoption of thrombolytic therapy in the management of acute myocardial infarction. *Am J Cardiol* 1988;61:510-514.
25. Hlatky MA, Cotugno HE, Mark DB, O'Connor CM, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970-1987. *Am J Cardiol* 1988;61:515-518.
26. Califf RM, O'Neill W, Stack RS, Aronson L, Mark DB, Mantell S, George BS, Candela RJ, Kereiakes DJ, Abbottsmith C, Topol EJ, and the TAMI Study Group. Failure of

- simple clinical measurements to predict perfusion status after intravenous thrombolysis. *Ann Int Med* 1988;108:658-622.
27. Califf RM, Harrell FE Jr., Lee KL, Rankin JS, Mark DB, Hlatky MA, Muhlbaier LH, Wechsler AS, Jones RH, Oldham HN, Pryor DB. Changing efficacy of coronary revascularization: implications for patient selection. *Circulation* 1988;78(Suppl I):185-191.
  28. Bounous EP, Mark DB, Pollock BG, Hlatky MA, Harrell FE Jr., Rankin JS, Wechsler AS, Pryor DB, Califf RM. Surgical survival benefits for coronary patients with left ventricular dysfunction. *Circulation* 1988;78(Suppl I):151-157.
  29. Mark DB, Hlatky MA, O'Connor CM, Pryor DB, Wall TC, Honan MB, Phillips HR, Califf RM. Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. *J Am Coll Cardiol* 1988;12:32A-43A.
  30. Hlatky MA, Mark DB, Califf RM, Pryor DB. Angina, myocardial ischemia and coronary disease: Gold standards, operational definitions, and correlations. *J Clin Epidemiol* 1989;42:381-384.
  31. Wall TC, Mark DB, Califf RM, Collins G, Burgess R, Skelton TN, Hinohara T, Kong DF, Mantell S, Aronson L, Hlatky MA, Cusma J, Stack RS, Pryor DB, Bashore TM. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: A qualitative and quantitative angiographic study. *Am J Cardiol* 1989;63:423-428.
  32. Kong DF, Lee KL, Harrell FE Jr., Boswick JM, Mark DB, Hlatky MA, Califf RM, Pryor DB. Clinical experience and predicting survival in coronary disease. *Arch Int Med* 1989;149:1177-1181.
  33. Califf RM, Harrell FE Jr., Lee KL, Rankin JS, Hlatky MA, Mark DB, Jones RH, Muhlbaier LH, Oldham N, Pryor DB. The evolution of medical and surgical therapy for coronary artery disease: a 15-year perspective. *JAMA* 1989;261:2077-2086.
  34. O'Connor CM, Mark DB, Hinohara T, Stack RS, Rendall D, Hlatky MA, Pryor DB, Phillips HR III, Califf RM. Rescue coronary angioplasty after failure of intravenous streptokinase in acute myocardial infarction: in-hospital and long-term outcomes. *J Inv Car* 1989;1:85-95.
  35. Mark DB, Hlatky MA, Califf RM, Morris JJ Jr., Sisson S, McCants CB, Lee KL, Harrell FE Jr., Pryor DB. Painless exercise ST deviation on the treadmill: long-term prognosis. *J Am Coll Cardiol* 1989;14:885-892.
  36. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. *Ann Int Med* 1989;111:1010-1022.

37. Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb F, Pryor DB. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). *Am J Cardiol* 1989;64:651-654.
38. Bengtson JR, Mark DB, Honan MB, Rendall DS, Hinohara T, Stack RS, Hlatky MA, Califf RM, Lee KL, Pryor DB. Detection of restenosis after elective coronary angioplasty using the exercise treadmill test. *Am J Cardiol* 1990;65:28-34.
39. Hlatky MA, Califf RM, Harrell FE Jr., Lee KL, Mark DB, Muhlbaier LH, Pryor DB. Clinical judgment and therapeutic decision making. *J Am Coll Cardiol* 1990;15:1-14.
40. Siegel WC, Mark DB, Hlatky MA, Harrell FE Jr., Pryor DB, Barefoot JC, Williams RB. Clinical correlates and prognostic significance of type A behavior and silent myocardial ischemia on the treadmill. *Am J Cardiol* 1989;64:1280-1283.
41. Honan MB, Bengtson JR, Pryor DB, Rendall DS, Stack RS, Hinohara T, Skelton TN, Califf RM, Hlatky MA, Mark DB. Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. *Circulation* 1989;80:1585-1594.
42. Lee JC, Bengtson JR, Lipscomb J, Bashore TM, Mark DB, Califf RM, Pryor DB, Hlatky MA. Feasibility and cost saving potential of outpatient cardiac catheterization. *J Am Coll Cardiol* 1990;15:378-384.
43. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor D, Wallace AG, Mark DB. Resource use and cost of initial coronary revascularization: coronary angioplasty versus coronary bypass surgery. *Circulation* 1990;82 (Suppl IV):IV-208 - IV-213.
44. Honan MB, Harrell FE Jr., Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA. Cardiac rupture mortality and the timing of thrombolytic therapy: a meta-analysis. *J Am Coll Cardiol* 1990;16:359-67.
45. Siegel, WC, Hlatky MA, Mark DB, Barefoot JC, Harrell FE Jr., Pryor DB, Williams RB. Effect of Type A behavior on exercise test outcome in coronary artery disease. *Am J Cardiol* 1990;66:179-182.
46. Davidson CJ, Mark DB, Pieper KS, Kisslo KB, Hlatky MA, Gabriel DA, Bashore TM. Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: analysis of 8517 patients. *Am J Cardiol* 1990;65:1481-1484.
47. O'Connor CM, Califf RM, Massey EW, Mark DB, Kereiakes DJ, Candela RJ, Abbottsmith C, George B., Stack RS, Aronson L, Mantell S, Topol EJ. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. *J Am Coll Cardiol* 1990;16:533-40.

48. Lee KL, Pryor DB, Pieper KS, Harrell FE Jr., Califf RM, Mark DB, Hlatky MA, Coleman RE, Cobb FR, Jones RH. Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. *Circulation* 1990;82:1705-1717.
49. Wall TC, Califf RM, Harrelson-Woodlief L, Mark DB, Honan M, Abbottsmith C, Candela R, Berrios E, Phillips HR, Topol EJ, TAMI Study Group. Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. *Am J Cardiol* 1990;66:1418-1421.
50. Belkin RN, Mark DB, Aronson L, Szwed H, Califf RM, Kisslo J. Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. *Am J Cardiol* 1991;67:496-500.
51. Mark DB, Sigmon K, Topol EJ, Kereiakes DJ, Pryor DB, Candela RJ, Califf RM. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. *Circulation* 1991;83:1186-1193.
52. Pryor DB, Shaw L, Harrell FE Jr., Lee KL, Hlatky MA, Mark DB, Muhlbaier LH, Califf RM. Estimating the likelihood of severe coronary artery disease. *Am J Med* 1991;90:553-562.
53. Califf RM, Fortin DF, Frid DJ, Harlan WR, Ohman EM, Bengtson JR, Nelson CL, Tchong JE, Mark DB, Stack RS. Restenosis after coronary angioplasty: an overview. *J Am Coll Cardiol* 1991;17:2B-13B.
54. Smith LR, Harrell FE Jr., Rankin JS, Califf RM, Pryor DB, Muhlbaier LH, Lee KL, Mark DB, Jones RH, Oldham HN, Glower DD, Reves JG. Determinants of early vs late cardiac death in patients undergoing coronary artery bypass surgery. *Circulation* 1991;84 (Suppl III): III-245-III-253.
55. Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relationship of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. *Am J Cardiol* 1991;68:973-75.
56. Mark DB, Shaw L, Harrell FE Jr., Hlatky MA, Lee KL, Bengtson JR, McCants CB, Califf RM, Pryor DB. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. *N Engl J Med* 1991;325:849-53.
57. Williams RB, Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DP, Hlatky MA, Siegler IC, Mark DB. Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. *JAMA* 1992;267:520-524.

58. Bickell NA, Pieper KS, Lee KL, Mark DB, Glower DD, Pryor DB, Califf RM. Referral patterns for coronary artery disease treatment: Gender bias or good clinical judgment? *Ann Int Med* 1992;116:791-797.
59. Harding MB, Leithe ME, Mark DB, Nelson CL, Harrison JK, Hermiller JB, Davidson CJ, Pryor DB, Bashore TM. Ergovine maleate testing during cardiac catheterization: a ten year perspective in 3,447 patients. *J Am Coll Cardiol* 1992;20:107-11.
60. Bengtson JR, Kaplan AJ, Pieper KS, Wildermann NM, Mark DB, Pryor DB, Stack RS, Phillips HR III, Califf RM. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. *J Am Coll Cardiol* 1992;20:1482-9.
61. Muhlbaier LH, Pryor DB, Rankin JS, Smith LR, Mark DB, Jones RH, Glower DD, Harrell FE Jr., Lee KL, Califf RM, Sabiston DC. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease: 20 years of follow-up. *Circulation* 1992;86 (Suppl II):198-204.
62. Mark DB, Lam LC, Lee KL, Clapp-Channing N, Williams RB, Pryor DB, Califf RM, Hlatky MA. Identification of patients with coronary disease at high risk for not returning to work: a prospective validation study. *Circulation* 1992;86(5):1485-1494.
63. Pryor DB, Shaw L, McCants CB, Lee KL, Mark DB, Harrell FE Jr., Muhlbaier LH, Califf RM. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Int Med* 1993;118:81-90.
64. Dudley RA, Harrell FE Jr., Smith LR, Mark DB, Califf RM, Pryor DB, Glower D, Lipscomb J, Hlatky MA. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. *J Clin Epidemiol* 1993;46:261-71.
65. Jollis JG, Ancukiewicz M, DeLong E, Pryor DB, Muhlbaier LH, Mark DB. Discordance of database designed for claims payment versus clinical information systems: implications for outcomes research. *Ann Int Med* 1993;119:844-50.
66. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler GP, Berdan LG, Hinohara T, Califf RM, CAVEAT Study Group. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. *N Engl J Med* 1993;329:221-7.
67. Mark DB, Lam LC, Lee KL, Jones RH, Pryor DB, Stack RS, Williams RB, Clapp-Channing NE, Hlatky MA. Effects of coronary angioplasty, coronary bypass surgery and medical therapy on employment in patients with coronary artery disease: a prospective comparison study. *Ann Intern Med* 1994;120:111-117.

68. Beckham JC, Barefoot JC, Haney TL, Williams RB, Mark DB. Pain coping strategies in patients referred for evaluation of angina pectoris. *J Cardiopulm Rehab* 1994;14:173-180.
69. Hillegass WB, Jollis JG, Granger CB, Ohman EM, Califf RM, Mark DB. Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. *Am J Cardiol* 1994;73:444-449.
70. Mark DB, Nelson CL, Califf RM, Harrell FE Jr., Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR, DeLong ER, Smith PK, Reves JG, Jollis JG, Tchong JE, Muhlbaier LH, Lowe JE, Phillips HR, Pryor DB. Continuing evolution of therapy for coronary artery disease: initial results from the era of coronary angioplasty. *Circulation* 1994;89(5):2015-2025.
71. Mark DB, Shaw LK, DeLong ER, Califf RM, Pryor DB. Absence of sex bias in the referral of patients for cardiac catheterization. *N Engl J Med* 1994;330:1101-1106.
72. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley K, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE III, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable angina: diagnosis and management. Clinical Practice Guideline Number X. AHCPR Publication No. 94-0682. March 1994.
73. Peterson ED, Jollis JG, Bebbuck JD, DeLong ER, Muhlbaier LH, Mark DB, Pryor DB. Changing mortality following myocardial revascularization in the elderly: the national Medicare experience. *Ann Int Med* 1994;121:919-927.
74. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. *Circulation* 1994;90:613-622.
75. Pilote L, Granger C, Armstrong PW, Mark DB, Hlatky MA. Differences in the treatment of myocardial infarction between the United States and Canada: A survey of physicians. *Medical Care* 1995;33(6):598-609.
76. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL, Clapp-Channing N, Sutherland W, Pilote L, Armstrong PW. Use of medical resources and quality of life outcomes after acute myocardial infarction in Canada versus the United States. *N Engl J Med* 1994;331(17):1130-1135.
77. Jollis JG, Peterson ED, DeLong ER, Mark DB, Collins SR, Muhlbaier LH, Pryor DB. The relation between the volume of coronary angioplasty procedures at hospitals treating Medicare beneficiaries and short-term mortality. *N Engl J Med* 1994;331:1625-1629.
78. Hlatky MA, Charles ED, Nobrega F, Gelman K, Johnstone I, Melvin J, Ryan T, Wiens R, Pitt B, Reeder G, Smith H, Whitlow P, Zone G, Mark DB and the BARI Study Group.

- Initial functional and economic status of patients with multivessel coronary disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol* 1995;75:34C-41C.
79. Hlatky MA, Lam LC, Lee KL, Clapp-Channing NE, Williams RB, Pryor DB, Califf RM, Mark DB. Job strain and the prevalence and outcome of coronary artery disease. *Circulation* 1995; 92(3):327-333.
  80. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: measuring and reducing errors. *Statistics in Medicine* 1996;15:361-387.
  81. Mark DB, O'Neill WW, Brodie B, Ivanhoe R, Knopf W, Taylor G, O'Keefe JH, Grines CL, Davidson-Ray L, Knight JD, Califf RM. Baseline and six-month costs of primary angioplasty for acute myocardial infarction: results from the Primary Angioplasty Registry. *J Am Coll Cardiol* 1995;26(3):688-95.
  82. Harlan WR III, Sandler SA, Lee KL, Lam LC, Mark DB. Importance of baseline functional and socioeconomic factors for participation in cardiac rehabilitation. *Am J Cardiol* 1995;76:36-39.
  83. Burnett RE, Blumenthal JA, Mark DB, Leimberger JD, Califf RM. Distinguishing between early and late responders to the symptoms of myocardial infarction. *Am J Cardiol* 1995; 75(15): 1019-1022.
  84. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong P, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr., Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. *N Engl J Med* 1995;332(21):1418-1424.
  85. Peterson ED, Cowper PA, Jollis JG, Bebbchuk JD, DeLong ER, Muhlbaier LH, Mark DB, Pryor DB. Outcomes of coronary artery bypass graft surgery in 24,461 patients aged 80 years or older. *Circulation* 1995;92(9):II85-91.
  86. Pilote L, Bourassa MG, Bacon C, Detre K, Mark DB, Pitt B, Reeder G, Rogers W, Ryan T, Schwartz L, Smith H, Whitlow P, Wiens R, Hlatky MA. Better functional status in American than Canadian patients with heart disease: an effect of medical care? *J Am Coll Cardiol* 1995;26(5): 1115-1120.
  87. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, Jacobs AK, Topol EJ for the CAVEAT Investigators. Characteristics and consequences of myocardial infarction following percutaneous coronary intervention: insights from CAVEAT. *J Am Coll Cardiol* 1995;25(7):1693-1699.

88. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ for the GUSTO-1 Investigators. Regional variation across the United States in the management of acute myocardial infarction. *N Engl J Med* 1995;333(9):565-572.
89. Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, Ohman EM, Leimberger JD, Mark DB, Califf RM. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 1995;76:1007-1013.
90. Omoigui NA, Califf RM, Pieper K, Keeler G, O'Hanesian MA, Berdan LG, Mark DB, Topol EJ. Peripheral vascular complications in the coronary angioplasty versus excisional atherectomy trial (CAVEAT). *J Am Coll Cardiol* 1995;26(4):922-30.
91. Fortin DF, Califf RM, Pryor DB, Mark DB. The way of the future redux. *Am J Cardiol* 1995;76(16):1177-1182.
92. Newby KL, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, Mark DB, Stebbins A, Van der Werf F, Gore JM, Topol EJ. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the GUSTO trial. *J Am Coll Cardiol* 1996;27:625-632.
93. Jones RH, Kesler K, Phillips HR, Mark DB, Smith PK, Nelson CL, Newman MF, Reves JG, Anderson RW, Califf RM. Long-term survival benefit of CABG and PTCA in patients with coronary artery disease. *J Thorac Cardiovasc Surg* 1996;111:1013-23.
94. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty. *Circulation* 1996;94:629-635.
95. Barefoot JC, Helms MJ, Mark DB, Haney TL, Blumenthal JA, Siegler IC, Williams RB. Depression and long term mortality risk in patients with coronary artery disease. *Am J Cardiol* 1996;78(6):613-617.
96. Liao L, Jollis JG, DeLong ER, Peterson ED, Morris KG, Mark DB. Impact of an interactive video on ischemic heart disease patient decision-making. *J Gen Int Med* 1996;11:373-376.
97. Cowper PA, DeLong ER, Peterson ED, Lipscomb J, Muhlbaier LH, Jollis JG, Pryor DB, Mark DB. Geographic variation in resource use for coronary artery bypass surgery. *Medical Care* 1997;35(4):320-333.
98. Pepine CJ, Holmes DR, Block PC, Brinker JA, Mark DB, Mullins CE, Nissen SE, Topol EJ, Williams DO and The Cardiac Catheterization Committee. Expert consensus document: coronary artery stents. *J Am Coll Cardiol* 1996;28(3):782-794.



99. Von Dras DD, Siegler IC, Williams RB, Clapp-Channing NE, Haney TL, Mark DB. Surrogate assessment of coronary artery disease patients' functional capacity. *Soc Sci and Med* 1997;44:1491-1502.
100. Talley JD, Ohman EM, Mark DB, George BS, Leimberger JD, Berdan LG, Davidson-Ray L, Rawert M, Lam LC, Phillips HR, Califf RM for the Randomized IABP Study Group. Economic implications of the prophylactic use of intraaortic balloon counterpulsation (IABP) in the setting of acute myocardial infarction. *Am J Cardiol* 1997;79:590-594.
101. Peterson ED, Shaw LK, DeLong ER, Pryor DB, Califf RM, Mark DB. Racial variation in the use of cardiac revascularization procedures: are the differences real? do they matter? *N Engl J Med* 1997;336(7):480-486.
102. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. *N Engl J Med* 1997;336(2):92-99.
103. Jollis JG, DeLong ER, Collins SR, Muhlbaier LH, Liao L, Mark DB. Outcome of acute myocardial infarction according to the specialty of the admitting physician. *N Engl J Med* 1996;335(25):1880-1887.
104. Eisenberg MJ, Califf RM, Cohen EA, Adleman AG, Mark DB, Topol EJ for the CAVEAT-I and CCAT Investigators. Use of evidence-based therapy in patients undergoing percutaneous coronary revascularization: a comparison of practice patterns in the United States, Europe and Canada. *Am J Cardiol* 1997;79:867-872.
105. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Califf RM, Knight JD, Mark DB. Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. *Proc AMIA Annu Fall Symp.* 1997:273-277.
106. DeLong ER, Peterson ED, DeLong DM, Muhlbaier LH, Hackett S, Mark DB. Comparison of risk-adjustment methods for provider profiling. *Statistics in Med* 1997;16:2645-2664.
107. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. The relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. *Circulation* 1997;96:2551-2556.
108. Jollis JG, Peterson ED, DeLong ER, Stafford JA, Muhlbaier LH, Mark DB. Relationship between physician angioplasty volume and outcome in elderly patients. *Circulation* 1997;95:2485-2491.

109. Hlatky MA, Bacon C, Boothroyd D, Mahanna E, Reves JG, Newman MF, Johnstone I, Winston C, Brooks MM, Rosen AD, Mark DB, Pitt B, Rogers W, Ryan T, Wiens R, Blumenthal JA. Cognitive function five years after randomization to coronary angioplasty or coronary artery bypass surgery. *Circulation* 1997;96:II11-115.
110. Cowper PA, Peterson ED, DeLong ER, Jollis JG, Muhlbaier LH, Mark DB. Impact of early discharge following coronary artery bypass surgery on rates of readmission and death. *J Am Coll Cardiol* 1997;30:908-914.
111. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WFC, Froelicher VF, Mark DB, Marwick T, McCallister BD, Thompson PD, Winters WL Jr., Yanowitz FG. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). *J Am Coll Cardiol* 1997;30:260-315; *Circulation* 1997;96:345-354.
112. Conlon PJ, Athirakul K, Kovalik E, Schwab SJ, Crowley J, Stack R, McCants B, Mark DB, Bashore TM, Albers F. Survival in renal vascular disease. *J of Am Soc Neph* 1998;9:252-256.
113. Simons GR, Shaw LJ, Eisenstein EL, Mark DB, Pritchett ELC. Cost effectiveness of in patient initiation of antiarrhythmic therapy for supraventricular tachycardias. *Am J Cardiol* 1997;80:1551-1557.
114. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AGG, Califf RM, Weatherley B, Cohen M. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. *Circulation* 1998;97:1702-1707.
115. Shah A, Wagner GS, Green CL, Crater SW, Sawchak ST, Wildermann NM, Mark DB, Waugh RA, Krucoff MW. Electrocardiographic differentiation of the ST-segment depression of acute myocardial injury due to the left circumflex artery occlusion from that of myocardial ischemia of non-occlusive etiology. *Am J Cardiol* 1997;80:512-514.
116. Shaw LJ, Peterson ED, Kesler KL, DeLong ER, Harrell FE Jr., Shaw LK, Muhlbaier LH, Mark DB. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. *Circulation* 1998;98:1622-1630.
117. Peterson ED, Jollis JG, DeLong ER, Muhlbaier LH, Mark DB. The effects of New York's bypass surgery provider profiling program on access to care and patient outcomes. *J Am Coll Cardiol* 1998;32:993-999.
118. Brummett BH, Babyak MA, Barefoot JC, Bosworth HB, Clapp-Channing NE, Siegler IC, Williams RB, Mark DB. Social support and hostility as predictors of depressive symptoms in cardiac patients one month following hospitalization: A prospective study. *Psychosomatic Med* 1998;60 (6):707-713.

119. Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing NE, Simoons M, Gore JL, Califf RM, Mark DB. Effects of stroke on medical resource use and costs in acute myocardial infarction. *Circulation* 1999;99(3):370-376.
120. Hlatky MA, Boothroyd DB, Brooks MM, Rosen A, Rogers WJ, Reeder GS, Smith HC, Ryan TJ, Pitt B, Whitlow PL, Wiens RD, Mark DB. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. *Am Heart J* 1999;138(2): 376-383.
121. Alexander KP, Shaw LJ, Shaw LK, DeLong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. *J Am Coll Cardiol* 1998;32(6):1657-1664.
122. Hlatky MA, Boothroyd D, Horine S, Winston C, Brooks MM, Rogers W, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Employment after randomization to coronary angioplasty or coronary bypass surgery. *Ann Intern Med* 1998;129:543-547.
123. Von Dras DD, Siegler IC, Barefoot JC, Williams RB, Mark DB. Coronary catheterization patient and wife's perceptions of social support: effects due to characteristics of recipient, provider, and their interaction. *Int J of Aging and Hum Dev* 2000;50(2):97-125.
124. Peterson ED, Cowper PA, DeLong ER, Zidar JP, Stack RS, Mark DB. Acute and long-term cost implications of coronary stenting. *J Am Coll Cardiol* 1999;33(6):1610-8.
125. Batchelor WB, Peterson ED, Mark DB, Knight JD, Granger CB, Ross AM, Armstrong PW, Califf RM. A comparison of US and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long term implications. *J Am Coll Cardiol* 1999;34(1):12-19.
126. Bosworth HB, Siegler IC, Brummett BH, Barefoot JC, Williams RB, Clapp-Channing NE, Mark DB. The association between self-rated health and mortality in a well-characterized sample of coronary artery disease patients. *Medical Care* 1999;37(12):1226-1236.
127. Bosworth HB, Siegler IC, Brummett BH, Barefoot JC, Williams RB, Vitaliano PP, Clapp-Channing NE, Lytle BL, Mark DB. The relationship between self-rated health and health status among coronary artery patients. *J of Aging and Health* 1999;11(4):565-584.
128. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell HE, Mahaffey KW, Davidson-Ray L, Topol EJ. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with Non-ST elevation acute coronary syndromes. *Circulation* 2000;101(4):366-371.
129. Bourassa MG, Brooks MM, Mark DB, Trudel J, Detre KM, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Smith HC, Whitlow PL, Wiens RD, Hlatky MA. Quality of life after

- coronary revascularization in the United States and Canada. *Am J Cardiol* 1999;85:548-553.
130. Pepine CJ, Mark DB, Bourassa MG, Chaitman BR, Davies RF, Knatterud GL, Forman S, Pratt CM, Sopko G, Conti CR for the ACIP Study Group. Cost estimates for treatment of cardiac ischemia. *Am J Cardiol* 1999;84:1311-1316.
  131. Khatri P, Babyak M, Croughwell N, Davis R, White W, Newman M, Reves JG, Mark DB, Blumenthal JA. Perception of cognitive function in older adults following coronary artery bypass surgery. *Health Psychology* 1999;18(3):301-6.
  132. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley JD, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM for the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. *Lancet* 1999; 354:2019-2024.
  133. Barefoot JC, Brummett BH, Clapp-Channing NE, Siegler IC, Vitaliano PP, Williams RB, Mark DB. Moderators of the effect of social support on depressive symptoms in cardiac patients. *Am J Cardiol* 2000;86:438-442.
  134. Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED, Armstrong PW, Van de Werf F, White HD, Topol EJ, Mark DB. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. *N Engl J Med* 2000;342(11):749-755.
  135. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Califf RM, Mark DB. Evaluating the potential “economic attractiveness” of new therapies in patients with non-ST elevation acute coronary syndrome. *Pharmacoeconomics* 2000;17(3):263-272.
  136. Chang W, Fu Y, Ohman EM, Gupta M, Morris A, Roth SN, Granger CB, Califf RM, Topol EJ, Mark DB, Armstrong PW for the North American GUSTO-I and GUSTO-III Investigators. Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from Canada and the United States. *Can J Cardiol* 2000;16(10):1231-1239.
  137. Lincoff AM, Mark DB, Tchong JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ for the EPILOG Investigators. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization. Results from the EPILOG randomized trial. *Circulation* 2000;102:2923-2929.
  138. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight JD, Mark DB, Granger CB, Agranatti DA, Mautner B, Ohman EM, Suarez LD, Armstrong PW, Gates K, Wagner GS for the GUSTO I Investigators. Use of resources, quality of life, and clinical

- outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). *Am J Cardiol* 2000;86:24-29.
139. Brummett BH, Barefoot JC, Siegler IC, Clapp-Channing NE, Lytle BL, Bosworth HB, Williams RB, Mark DB. Characteristics of socially isolated cardiac patients at elevated risk for mortality. *Psychosomatic Medicine* 2001;63:267-272.
  140. Bosworth HB, Feaganes JR, Vitaliano PP, Mark DB, Siegler IC. Personality and coping with a common stressor: cardiac catheterization. *J Behavioral Med* 2001;24(1):17-31.
  141. Newman MF, Kirchner J, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA, for the Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. *N Engl J Med* 2001;344:395-402.
  142. Barefoot JC, Brummett BH, Helms MJ, Mark DB, Siegler IC, Williams RB. Depressive symptoms and survival of patients with coronary artery disease. *Psychosomatic Med* 2000;62:790-795.
  143. Bosworth HB, Siegler IC, Olsen MK, Brummett BH, Barefoot JC, Williams RB, Clapp-Channing NE, Mark DB. Social support and quality of life in patients with coronary artery disease. *Quality of Life Research* 2000;9:829-839.
  144. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, Mark DB. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. *Medical Care* 2001;39(8):824-835.
  145. Hassan SA, Hlatky M, Boothroyd D, Winston C, Mark DB, Brooks MM, Eagle KA for the BARI/SEQOL Investigators. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Med* 2001;110:260-266.
  146. DeLong ER, Nelson CL, Wong JB, Pryor DB, Peterson ED, Lee KL, Mark DB, Califf RM, Pauker SG. Using observational data to estimate prognosis: an example using a coronary artery disease registry. *Stat Med* 2001;20:2505-2532.
  147. Grigore AM, Mathew J, Grocott HP, Reves JG, Blumenthal JA, White WD, Smith PK, Jones RH, Kirchner JL, Mark DB, Newman MF, Neurological Outcome Group and C.A.R.E. Investigators of the Duke Heart Center. Prospective randomized trial of normothermic versus hypothermic cardiopulmonary bypass on cognitive function after coronary artery bypass graft surgery. *Anesthesiology* 2001;95:1110-1119.
  148. Newman MF, Grocott HP, Mathew JP, White WD, Landolfo K, Reves JG, Laskowitz DT, Mark DB, Blumenthal JA, Neurological Outcome Research Group and C.A.R.E. Investigators of the Duke Heart Center. Report of the substudy assessing the impact of

- neurocognitive function on quality of life five years after cardiac surgery. *Stroke* 2001;32:2874-2881.
149. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. *Kidney International* 2001;60(4):1490-1497.
  150. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJ, Weintraub WS, Mitchell KR, Morrisson SL, Brindis RG, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Ellis SG, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, Riner RN, Schwartz JB, Shaw RE, Shemin RJ, Van Fossen DB, Verrier ED, Watkins MW, Phoubandith DR, Furnelli T. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). *J Am Coll Cardiol* 2001;38:2114-2130.
  151. Kandzari DE, Lam LC, Eisenstein EL, Clapp-Channing NE, Fine JT, Califf RM, Mark DB, Jollis JG. Advanced coronary artery disease: Appropriate end points for trials of novel therapies. *Am Heart J* 2001;142(5):843-851.
  152. Khatri P, Babyak M, Croughwell ND, Davis R, White WD, Newman MF, Reves JG, Mark DB, Blumenthal JA. Temperature during coronary artery bypass surgery affects quality of life. *Ann Thorac Surg* 2001;71:110-116.
  153. Cowper PA, DeLong ER, Peterson ED, Hannan EL, Ray KT, Racz M, Mark DB. Variability in cost of coronary bypass surgery in New York State: potential for cost savings. *Am Heart J* 2002;143(1):130-139.
  154. Eisenstein EL, Shaw LK, Nelson CL, Anstrom KJ, Hakim Z, Mark DB. Obesity and long-term clinical and economic outcomes in coronary artery disease patients. *Obes Res* 2002;10(2):83-91.
  155. Eisenstein EL, Nelson CL, Simon TA, Smitten AL, Lapuerta P, Mark DB. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. *Am Heart J* 2002;143(6):1112-1117.
  156. Mazur W, Kaluza GL, Sapp S, Balog C, Topol EJ, Mark DB, Ellis SG, Kereiakes DJ, Lincoff AM, Kleiman NS. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. *Am Heart J* 2002;143(4):594-601.

157. Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. The cost of prevention: can we afford it? Can we afford not to do it? *J Am Coll Cardiol* 2002;40:579-651.
158. Blumenthal JA, Babyak M, Wei J, O'Connor C, Waugh R, Eisenstein E, Mark DB, Sherwood A, Woodley PS, Irwin RJ, Reed G. Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. *Am J Cardiol* 2002;89(2):164-8.
159. Fu Y, Chang WC, Mark DB, Califf RM, Mackenzie B, Granger CB, Topol EJ, Hlatky MA, Armstrong PW. Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIB trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. *Circulation* 2000;102(12):1375-81.
160. Brummett BH, Babyak MA, Mark DB, Williams RB, Siegler IC, Clapp-Channing NE, Barefoot JC. Predictors of smoking cessation in patients with a diagnosis of coronary artery disease. *J Cardpulm Rehabil* 2002;22(3):140-142.
161. Batchelor WB, Peterson ED, Mark DB, Knight JD, Granger CB, Armstrong PW, Califf RM. Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada. *Am Heart J* 2003;145(2):349-355.
162. Mark DB, Hlatky MA. Medical economics in the assessment of value in cardiovascular medicine. Part I. *Circulation* 2002;106(4):516-520.
163. Mark DB, Hlatky MA. Medical economics in the assessment of value in cardiovascular medicine. Part II. *Circulation* 2002;106(5):626-630.
164. Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM. A national survey of contract provisions in clinical trial agreements between academic medical centers and industry sponsors. *N Engl J Med* 2002; 347(17):1335-1341.
165. Newby LK, Hasselblad V, Armstrong PW, Van de Werf F, Mark DB, Topol EJ, Califf RM. Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. *Eur Heart J* 2003; 24:182-189.
166. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr., Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr., American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice

Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *Circulation* 2002;106(14):1883-1892.

167. Phillips Bute B, Mathew J, Blumenthal JA, Welsh-Bohmer K, White WD, Mark DB, Landolfo K, Newman MF for the Neurological Outcome Research Group and C.A.R.E. Investigators of the Duke Heart Center. Female gender is associated with impaired quality of life one year following CABG surgery. *Psychosomatic Med* 2003;65(6):944-951.
168. Brummett BH, Babyak MA, Siegler IC, Mark DB, Williams RB, Barefoot JC. Effect of smoking and sedentary behavior on the association between depressive symptoms and mortality from coronary heart disease. *Am J Cardiol* 2003;92(5):529-532.
169. Blumenthal JA, Lett H, Babyak MA, Smith P, White W, Mark DB, Matthew J, Newman M, for the NORG Investigators. Depression as a risk factor for mortality following coronary artery bypass surgery. *Lancet* 2003;362(9384):604-609.
170. Rao SV, Kaul P, Newby LK, Lincoff AM, Hochman J, Harrington RA, Mark DB, Peterson ED. Poverty, process of care, and outcome in acute coronary syndromes. *J Am Coll Cardiol* 2003;41(11):1948-1954.
171. Mark DB, Shaw LJ, Lauer MS, O'Malley PG, Hiedenreich P. 34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective? *J Am Coll Cardiol* 2003;41(11):1906-1917.
172. Kaul P, Armstrong PW, Fu Y, Knight JD, Clapp-Channing NE, Sutherland W, Granger CB, Mark DB for the GUSTO-IIb Investigators. Impact of different patterns of invasive care on quality of life outcomes in non-ST elevation acute coronary syndrome patients: results from the GUSTO IIb Canada-United States sub-study. *Can J Cardiol* 2004;20(8):760-766.
173. Grunberg GE, Crater SW, Green CL, Seskevich J, Lane JD, Koenig HG, Bashore TM, Morris KG, Mark DB, Krucoff MW. Correlations between preprocedure mood and clinical outcome in patients undergoing coronary angioplasty. *Cardiol Rev* 2003;11(6):309-317.
174. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, Owen WF. Chronic kidney disease, mortality and treatment strategies among patients with clinically significant coronary artery disease. *J Am Soc Nephrol* 2003;14(9):2373-2380.
175. Wang SS, Mendelson DN, Schulman KA, Mark DB. Exploring options for improving healthcare. *Am Heart J* 2004;147(1):23-30.



176. Kong DF, Eisenstein EL, Sketch MH, Zidar JP, Ryan T, Harrington RA, Newman MF, Smith PK, Mark DB, Califf RM. Economic impact of drug-eluting stents on hospital systems: a disease-state model. *Am Heart J* 2004;147(3):449-456.
177. Brummett BH, Babyak MA, Mark DB, Clapp-Channing NE, Siegler IC, Barefoot JC. Prospective study of perceived stress in cardiac patients. *Ann Behav Med* 2004;27(1):22-30.
178. Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, Aylward P, Granger CB, Van de Werf F, Armstrong PW. International differences in evolution of early discharge after acute myocardial infarction. *Lancet* 2004;363(9408):511-517.
179. Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. *J Am Coll Cardiol* 2004;43(4):576-582.
180. Eisenstein EL, Bethea CF, Muhlbaier LH, Davidian M, Peterson ED, Stafford JA, Mark DB. Surgeons' economic profiles: can we get the "right" answers? *J Med Systems* 2005;29(2):111-124.
181. Kaul P, Armstrong PW, Chang W, Naylor CD, Granger CB, Lee KL, Peterson ED, Califf RM, Topol EJ, Mark DB. Long-term mortality of patients with acute myocardial infarction in the US and Canada: a comparison of patients enrolled in GUSTO I. *Circulation* 2004;110:1754-1760.
182. Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, Mark DB. Economic analysis of the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. *Am Heart J* 2005; 149(4):637-644.
183. Barbagelata A, Califf RM, Sgarbossa EB, Pinski S, Goodman SG, Knight JD, Mark DB, Granger CB, Armstrong PW, Perez de la Hoz R, Swieszkowski S, Gates K, Wagner GS for the GUSTO-I Investigators. Prognostic value of electrocardiographic measurement of infarct size after thrombolysis: a GUSTO-I economics and quality-of-life substudy. *Am Heart J* 2004;148(5):795-802.
184. Boyle SH, Williams RB, Mark DB, Brummett BH, Siegler IC, Barefoot JC. Hostility as a predictor of survival after coronary artery disease. *Psychosomatic Med* 2004;66(5):629-632.
185. Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. *Circulation* 2004;110:1960-1966.

186. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray, LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;352:225-237.
187. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Frech FH, Glick HA, Gnanasakthy A, Gause D, Hlatky MA, McBurney CR, Khan ZM, O'Brien BJ, Tsiatis AA, Willan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: proceedings of a workshop. *Am Heart J* 2005;149(3):434-443.
188. Al-Khatib SM, Anstrom KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, Li Y, O'Connor CM, Shaw LK, Califf RM. Clinical and economic implications of the multi-center automatic defibrillator implantation trial II. *Ann Intern Med* 2005;142(8):593-600.
189. Brummett BH, Boyle SH, Siegler IC, Williams RB, Mark DB, Barefoot JC. Ratings of positive and depressive emotion as predictors of mortality in coronary patients. *Int J Cardiol* 2005;199(2):213-216.
190. Brummett BH, Mark DB, Siegler IC, Williams RB, Babyak MA, Clapp-Channing NE, Barefoot JC. Perceived social support as a predictor of mortality in coronary patients: effects of smoking, sedentary behavior, and depressive symptoms. *Psychosom Med* 2005;67(1):40-45.
191. DeLong ER, Lytle BL, Cowper PA, Alexander KP, Peterson ED, Mark DB. Research, managed care, and patient privacy: challenges to successful collaboration. *J Clin Outcomes Manage* 2005;12(3):151-156.
192. Krucoff MW, Crater SW, Gallup D, Blankenship JC, Cuffe M, Guarneri M, Krieger RA, Kshetry VR, Morris K, Oz M, Pichard A, Koenig H, Mark DB, Lee KL. Music, imagery, touch and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic TRAINings (MANTRA) II Study. *Lancet* 2005;366(9481):211-217.
193. Liao L, Kong DF, Shaw LK, Sketch MH, Milano CA, Lee KL, Mark DB. A new anatomic score for prognosis after cardiac catheterization in patients with previous bypass surgery. *J Am Coll Cardiol* 2005;46(9):1684-1692.
194. Liao L, Jollis JG, Anstrom KJ, Whellan DJ, Kitzman DW, Aurigemma GP, Mark DB, Schulman KA, Gottdiener JS. Costs for heart failure with normal versus reduced ejection fraction. *Arch Intern Med* 2006; 166(1):112-8.
195. Boyle SH, Williams RB, Mark DB, Brummett BH, Siegler IC, Barefoot JC. Hostility, age, and mortality in a sample of cardiac patients. *Am J Cardiol* 2005;96:64-66.

196. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadish A, Moss A, Feldman AM, Ellenbogen KA, Singh S, Califf RM; Expert panel participating in a Duke Clinical Research Institute-sponsored conference. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. *Am Heart J* 2005;149(6):1020-1034.
197. Kaul P, Newby LK, Fu Y, Mark DB, Goodman SG, Wagner GS, Harrington RA, Granger CB, Van de Werf F, Ohman EM, Armstrong PW; VIGOUR Group. Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns. *Heart* 2005;91(7):876-881.
198. Hochman JS, Lamas GA, Knatterud GL, Buller CE, Dzavik V, Mark DB, Reynolds HR, White HD, for the Occluded Artery Trial Research Group. Design and methodology of the Occluded Artery Trial (OAT). *Am Heart J* 2005;150(4):627-642.
199. Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JWH, Garrigue S, Goresan J, Hayes DL, Kass DA, Knuuti J, Leclercq C, Linde C, Mark DB, Monaghan MJ, Nihoyannopoulos P, Schalij MJ, Stellbrink C, Yu C. Cardiac resynchronization therapy: part 1—issues before device implantation. *JACC* 2005; 46(12):2153-67.
200. Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JWH, Garrigue S, Goresan J, Hayes DL, Kass DA, Knuuti J, Leclercq C, Linde C, Mark DB, Monaghan MJ, Nihoyannopoulos P, Schalij MJ, Stellbrink C, Yu C. Cardiac resynchronization therapy: part 2—issues during and after device implantation and unresolved questions. *JACC* 2005; 46(12):2168-82.
201. Shaw LJ, Olson MB, Kip K, Kelsey SF, Johnson BD, Mark DB, Reis SE, Mankad S, Rogers WJ, Pohost GM, Arant CB, Wessel TR, Chaitman BR, Sopko G, Handberg E, Pepine CJ, Bairey Merz CN. The value of estimated functional capacity in estimating outcome: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. *JACC* 2006;47(3):S36-S43.
202. Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davison-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH, for the SCD-HeFT Investigators. Cost effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Circulation* 2006;114(2):135-142.
203. Phillips-Bute B, Mathew JP, Blumenthal JA, Grocott HP, Laskowitz DT, Jones RH, Mark DB, Newman MF. Association of neurocognitive function and quality of life 1 year after coronary artery bypass graft (CABG) surgery. *Psychosomatic Med* 2006;68:369-375.
204. Eisenstein EL, Yusuf S, Bindal V, Bourassa MG, Horney A, Collins JF, Mark DB: DIG Investigators. What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. *J Card Fail* 2006;12(5):336-342.

205. Newman MF, Mathew JP, Grocott HP, Mackensen GB, Monk T, Welsh-Bohmer KA, Blumenthal JA, Laskowitz DT, Mark DB, for the Neurologic Outcome Research Group. Central nervous system injury associated with cardiac surgery. *Lancet* 2006;368(9536):694-703.
206. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin FV, Mark DB, Knatterud GL, the Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med* 2006;355(23):2395-2407.
207. Cowper PA, DeLong ER, Hannan EL, Muhlbaier LH, Lytle BL, Jones RH, Holman WL, Pokorny JJ, Stafford JA, Mark DB, Peterson ED. Is early too early? Effect of shorter stays after bypass surgery. *Ann Thorac Surg* 2007;83:100-107.
208. Cowper PA, DeLong ER, Hannan EL, Muhlbaier LH, Lytle BL, Jones RH, Holman WL, Pokorny JJ, Stafford JA, Mark DB, Peterson ED. Trends in postoperative length of stay after bypass surgery. *Am Heart J* 2006;152:1194-1200.
209. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA* 2007;297(2):159-168.
210. Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB, Lee KL, Bardy GH; SCD-HeFT Investigators. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. *Am Heart J* 2006;152(5):974.e7-11.
211. Felker GM, Peterson JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. *CMAJ* 2006;175(6):611-617.
212. Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, Mark DB, Lee KL, Bardy GH. The risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Circulation* 2007;115(20):2637-2641.
213. Haan CK, Milford-Beland S, O'Brien S, Mark DB, Dillum M, Ferguson TB, Peterson ED. Impact of residency status on perfusion times and outcomes for coronary artery bypass surgery. *Ann Thorac Surg* 2007;83(6):2103-2110.
214. Patel MR, Hurwitz L, Orlando L, McCrory DC, Sanders G, Matchar DB, Mark DB. Non-invasive imaging for coronary artery disease: a technology assessment for the Medicare Coverage Advisory Commission. *Am Heart J* 2007;153(2):161-174.
215. Al-Khatib SM, Sanders GD, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis A, Curtis J, Fain E, Gersh BJ, Gold MR, Haghghi-Mood A, Hammill SC, Healy J, Hlatky

- MA, Hohnloser S, Kim RJ, Lee KL, Mark DB, Mianulli M, Mitchell B, Prystowsky EN, Smith J, Steinhaus D, Zareba W, for an expert panel participating in a Duke's Center for the Prevention of Sudden Cardiac Death conference. Preventing tomorrow's sudden cardiac death today. Part I: current data on risk stratification for sudden cardiac death. *Am Heart J* 2007;153(6):941-950.
216. Sanders GD, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis AB, Curtis JP, Domanski M, Fain E, Gersh BJ, Gold MR, Goldberger J, Haghghi-Mood A, Hammill SC, Harder J, Healy J, Hlatky MA, Hohnloser SH, Lee KL, Mark DB, Mitchell B, Phurrough S, Prystowsky EN, Smith JM, Stockbridge N, Temple R, for an expert panel participating in a Duke Center for the Prevention of Sudden Cardiac Death-sponsored conference. Preventing tomorrow's sudden cardiac death today. Part II: translating sudden cardiac death risk assessment strategies into practice and policy. *Am Heart J* 2007;153(6):951-959.
217. Mindel J, Anderson J, Hellkamp A, Mark DB, Lee KL, Bardy GH, for the SCD-HeFT Investigators. Absence of bilateral vision loss from amiodarone. *Am Heart J* 2007;153(5):837-842.
218. Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH, for the STICH Investigators. The rationale and design of the surgical treatment for ischemic heart failure (STICH) trial. *J Thorac Cardiovasc Surg* 2007;134:1540-1547.
219. Lamas GA, Knight JD, Sweeney MO, Mianulli M, Khalighi K, Cook JR, Silverman R, Rosenthal L, Clapp-Channing NE, Lee KL, Mark DB. Impact of rate modulated pacing on quality of life and exercise capacity—evidence from the Advanced Elements of Pacing Trial (ADEPT). *Heart Rhythm* 2007;4:1125-1132.
220. Jonassaint CR, Boyle SH, Williams RB, Mark DB, Siegler IC, Barefoot JC. Facets of openness predict mortality in patients with cardiac disease. *Psychosom Med* 2007;69(4):319-322.
221. Olshansky B, Wood F, Hellkamp AS, Poole JE, Anderson J, Johnson GW, Boineau R, Domanski MJ, Mark DB, Lee KL, Bardy GH, for the SCD-HeFT Investigators. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Am Heart J* 2007;153(6):1089-1094.
222. Chen JC, Kaul P, Levy JH, Haverich A, Menasche P, Smith PK, Carrier M, Verrier ED, Van de Werf F, Burge R, Finnegan P, Mark DB, Shernan SK for the PRIMO-CABG Investigators. Myocardial infarction following coronary artery bypass graft surgery increases health resource utilization. *Crit Care Med* 2007;35(5):1296-1301.
223. Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE, Mark DB, Lee KL, Bardy GH for the SCD-HeFT Investigators. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with

- implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Am Heart J* 2007;153(4):573-578.
224. Liao L, Anstrom KJ, Gottdiener JS, Pappas PA, Whellen DJ, Kitzman DW, Aurigemma GP, Mark DB, Schulman KA, Jollis JG. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. *Am Heart J* 2007;153(2):245-252.
225. Mark DB, Van de Werf FJ, Simes RJ, White HD, Wallentin LC, Califf RM, Armstrong PW, for the VIGOUR Group. Cardiovascular disease on a global scale: defining the path forward for research and practice. *Eur Heart J* 2007;28:2678-2684.
226. Rao SV, Kaul PR, Liao L, Armstrong PW, Ohman EM, Granger CB, Califf RM, Harrington RA, Eisenstein EL, Mark DB. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2008;155(2):369-374.
227. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Poole JE, Lee KL, Bardy GH; for the SCD-HeFT Investigators. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Am Heart J* 2008;155(3):501-506.
228. Bardy GH, Lee KL, Mark DB, Poole JE, Toff WD, Tonkin AM, Smith W, Dorian P, Yallop J, Packer DL, White RR, Longstreth W Jr., Anderson J, Johnson G, Bischoff E, Munkers C, Brown A, McNulty S, Davidson-Ray L, Clapp-Channing NE, Rosenberg Y, Salive M, Schron EB; for the HAT Investigators. Rationale and design of the Home Automatic External Defibrillator Trial (HAT). *Am Heart J* 2008;155(3):445-454.
229. Russo AM, Poole JE, Mark DB, Anderson J, Hellkamp AS, Lee KL, Johnson GW, Domanski M, Bardy GH. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. *J Cardiovasc Electrophysiol* 2008;19(7):720-724.
230. Olshansky B, Poole JE, Johnson G, Anderson J, Hellkamp AS, Packer D, Mark DB, Lee KL, Bardy GH; SCD-HeFT Investigators. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. *J Am Coll Cardiol* 2008;51(13):1277-1282.
231. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L, Lee KL, Bardy GH, for the SCD-HeFT Investigators. Quality of life outcomes with defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *N Engl J Med* 2008;359(10):999-1008. PMID: PMC2823628.

232. Matchar DB, Mark DB. Strategies for incorporating resource allocation and economic considerations: American College of Chest Physicians evidence-based clinical practice guidelines (8<sup>th</sup> edition). *Chest* 2008;133:132S-140S.
233. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8<sup>th</sup> edition). *Chest* 2008;133:776S-814S.
234. Kim JH, Newby LK, Clare RM, Shaw LK, Lodge AJ, Smith PK, Jolicoeur EM, Rao SV, Becker RC, Mark DB, Granger CB. Clopidogrel use and bleeding after coronary artery bypass graft surgery. *Am Heart J* 2008;156(5):886-892.
235. Eisenstein EL, Sun JL, Anstrom KJ, Stafford JA, Szczech LA, Muhlbaier LH, Mark DB. Re-evaluating the volume-outcome relationship in hemodialysis patients. *Health Policy* 2008;88(2-3):317-325.
236. Al-Khatib SM, Hellkamp AS, Lee KL, Anderson J, Poole JE, Mark DB, Bardy GH, for the SCD-HeFT Investigators. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Cardiovasc Electrophysiol* 2008;19(10):1059-1065.
237. Bardy GH, Lee KL, Mark DB, Poole JE, Toff WD, Tonkin AM, Smith W, Dorian P, Packer DL, White RD, Longstreth WT Jr, Anderson J, Johnson G, Bischoff E, Yallop JJ, McNulty S, Ray LD, Clapp-Channing NE, Rosenberg Y, Schron EB; HAT Investigators. Home use of automated external defibrillators for sudden cardiac arrest. *N Engl J Med* 2008;358(17):1793-1804.
238. Nelson CL, Sun JL, Tsiatis AA, Mark DB. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology. *Stat Med* 2008;27(26):5525-5555.
239. Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Anderson J, Chung K, Wong WS, Mark DB, Lee KL, Bardy GH, for the SCD-HeFT Investigators. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). *J Am Coll Cardiol* 2008;52 551-556.
240. Anstrom KJ, Kong DF, Shaw LK, Califf RM, Kramer JM, Peterson ED, Rao SV, Matchar DB, Mark DB, Harrington RA, Eisenstein EL. Long-term clinical outcomes following coronary stenting. *Arch Intern Med* 2008;168(15):1647-1655.
241. Jolicoeur EM, Granger CB, Henry TD, Holmes DJ, Pepine CJ, Mark D, Chaitman BR, Gersh BJ, Ohman EM, Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease: part 1: contemporary and emerging therapies. *Am Heart J* 2008;155(3):418-434.

242. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES. Depression and coronary heart disease: recommendations for screening, referral, and treatment from the American Heart Association Prevention Committee on the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by American Psychiatric Association. *Circulation* 2008;118:1768-1775.
243. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Mark DB, Lee KL, Bardy GH, for the SCD-HeFT Investigators. Prognostic importance of defibrillator shocks in patients with heart failure. *N Engl J Med* 2008;359(10):1009-1017.
244. Mark DB, Pan W, Clapp-Channing NE, Anstrom KJ, Ross JR, Fox RS, Devlin GP, Martin CE, Adlbrecht C, Cowper PA, Davidson-Ray L, Cohen EA, Lamas GA, Hochman JS, for the Occluded Artery Trial Investigators. Quality of life after late invasive therapy for occluded arteries. *N Engl J Med* 2009;360:774-783. PMID: PMC2724193.
245. Kruk M, Kadziela J, Reynolds HR, Forman SA, Sadowski Z, Barton BA, Mark DB, Maggioni AP, Leor J, Webb JG, Kapeliovich M, Marin-Neto JA, White HD, Lamas GA, Hochman JS. Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction. Results from the Occluded Artery Trial (OAT). *J Am Coll Cardiol Intv* 2008;1:511-520. PMID: PMC2635493.
246. Harrington RA, Califf RM, Hodgson PK, Peterson ED, Roe MT, Mark DB. Careers for clinical investigators. *Circulation* 2009;119:2945-2950.
247. Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, Lee KL, Bardy GH. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans Sudden Cardiac Death in Heart Failure trial substudy. *Circulation* 2008;118:2022-2028. PMID: PMC2777708.
248. Gula LJ, Klein GJ, Hellkamp AS, Massel D, Krahn AD, Skanes AC, Yee R, Anderson J, Johnson GW, Poole JE, Mark DB, Lee KL, Bardy GH. Ejection fraction assessment and survival: An analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Am Heart J* 2008;156:1196-200. PMID: PMC2644051.
249. Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. *Am Heart J* 2008;156(4):698-705.



250. Mark DB, Knight JD, Velazquez EJ, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ, for the Surgical Treatment for Ischemic Heart Failure (STICH) Trial Investigators. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. *Am Heart J* 2009;157:837-844. PMID: PMC2694042.
251. Eisenstein EL, Sun JL, Anstrom KJ, Stafford JA, Szczech LA, Muhlbaier LH, Mark DB. Do income level and race influence survival in patients receiving hemodialysis? *Am J Med* 2009;122(2):170-180.
252. Kaul P, Naylor CD, Armstrong PW, Mark DB, Theroux P, Dagenais GR. Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. *Can J Cardiol* 2009;25(7):e225-e231. PMID: PMC2723031.
253. Eisenstein EL, Sun JL, Anstrom KJ, DeLong ER, Szczech LA, Mark DB. Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patients. *J Med Syst* 2009;33(4):287-297.
254. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, Maggioni AP, Anand I, Poole-Wilson PA, Fishbein DP, Johnson G, Anderson J, Mark DB, Bardy GH. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. *Circulation* 2009;120(10):835-842.
255. Berger JS, Melloni C, Wang TY, Dolor RJ, Frazier CG, Samad Z, Peterson ED, Mark DB, Newby LK. Reporting and representation of race/ethnicity in published randomized trials. *Am Heart J* 2009;158(5):742-747.
256. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the Sudden Cardiac Death in Heart Failure Trial. *Circulation* 2009;120(22):2170-2176.
257. Brummett BH, Morey MC, Boyle SH, Mark DB. Prospective study of associations among positive emotion and functional status in older patients with coronary artery disease. *J Gerontol B Psychol Sci Soc Sci* 2009;64(4):461-469. PMID: PMC2697502.
258. Katz JN, Shah BR, Volz EM, Horton JR, Shaw LK, Newby LK, Granger CB, Mark DB, Califf RM, Becker RC. Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. *Crit Care Med* 2010;38(2):375-381.
259. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK. Representation of women in randomized clinical trials of cardiovascular disease prevention. *Circ Cardiovasc Qual Outcomes* 2010;3:135-142.

260. Al-Khatib SM, Calkins H, Eloff BC, Packer DL, Ellenbogen KA, Hammill SC, Natale A, Page RL, Prystowsky E, Jackman WM, Stevenson WG, Waldo AL, Wilber D, Kowey P, Yaross MS, Mark DB, Reiffel J, Finkle JK, Marinac-Dabic D, Pinnow E, Sager P, Sedrakyan A, Canos D, Gross T, Berliner E, Krucoff MW, for an expert panel participating in this meeting. Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a cardiac safety research consortium “incubator” think tank. *Am Heart J* 2010;159:17-24.
261. Mark DB, Anstrom KJ, McNulty SE, Flaker GC, Tonkin AM, Smith WM, Toff WD, Dorian P, Clapp-Channing NE, Anderson J, Johnson G, Schron EB, Poole JE, Lee KL, Bardy GH. Quality of life effects of automatic external defibrillators in the home: results from the Home Automatic External Defibrillator Trial (HAT). *Am Heart J* 2010;159:627-634. PMID: PMC2851635.
262. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, McB. Hodgson J, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS. ACCF/ACR/AHA/ASNC/NASCI/SAIP/SCAI/SCCT 2010 Expert consensus document on coronary CT angiography. *J Am Coll Cardiol* 2010;55(23):2663-2699. *Circulation* 2010;121:2509-2543. *Catheter Cardiovasc Interv* 2010;76:E1-E42.
263. Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O’Gara P, Rubin GD, Kramer CM, Taylor AJ, Berman D, Brown A, Chaudhry FA, Cury RC, Desai MY, Einstein AJ, Gomes AS, Harrington R, Hoffmann U, Khare R, Lesser J, McGann C, Rosenberg A, Schwartz R, Shelton M, Smetana GW, Smith SC Jr, Wolk MJ, Allen JM, Bailey S, Douglas PS, Hendel RC, Kramer CM, Min J, Patel MR, Shaw L, Stainback RF. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol.* 2010;56(22):1864-94. *Circulation.* 2010 Nov 23;122(21):e525-55. *J Cardiovasc Comput Tomogr* 2010;4(6):e1-407.e33.
264. Bennett-Guerrero E, Pappas TN, Koltun WA, Fleshman JW, Lin M, Garg J, Mark DB, Marcet JE, Remzi FH, George VV, Newland K, Corey GR, for the SWIPE-2 Trial Group. Gentamicin-collagen sponge for prophylaxis in colorectal surgery. *N Engl J Med* 2010; 363:1038-1049.
265. Bennett-Guerrero E, Ferguson TB Jr, Lin M, Garg J, Mark DB, Scavo VA Jr, Kouchoukos N, Richardson JB Jr, Pridgen RL, Corey GR; SWIPE-1 Trial Group. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. *JAMA* 2010;304(7):755-762.

266. Strauss DG, Poole JE, Wagner GS, Selvester RH, Miller JM, Anderson J, Johnson G, McNulty SE, Mark DB, Lee KL, Bardy GH, Wu KC. An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. *Heart Rhythm* 2011;8(1):38-45. PMID: PMC3010478.
267. Martin SS, Karra R, Mark DB. Pheochromocytoma presenting as fever of unknown origin. *Am J Med* 2011;124(2):e5-6.
268. Piccini JP, Al-Khatib SM, Hellkamp AS, Anstrom KJ, Poole JE, Mark DB, Lee KL, Bardy GH. Mortality benefits from implantable cardioverter defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Heart Rhythm* 2011;8(3):393-400.
269. Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann F, Breithardt G, Brugada J, Crijns H, Ellinor PT, Mark D, Naccarelli G, Packer D, Tamargo J. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. *J Cardiovasc Electrophysiol* 2010;21:946-958.
270. Devlin G, Reynolds HR, Mark DB, Rankin JM, Carvalho AC, Vozzi C, Sopko G, Caramori P, Dzavik V, Ragosta M, Forman SA, Lamas GA, Hochman JS. Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). *Am Heart J* 2011;161:84-90. PMID: PMC3004529.
271. Al-Khatib SM, Hellkamp A, Curtis J, Mark D, Peterson E, Sanders GD, Heidenreich PA, Hernandez AF, Curtis LH, Hammill S. Non-evidence-based ICD implantations in the United States. *JAMA* 2011;305(1):43-49.
272. Barefoot JC, Brummett BH, Williams RB, Siegler IC, Helms MJ, Boyle SH, Clapp-Channing NE, Mark DB. Recovery expectations and long-term prognosis of patients with coronary heart disease. *Arch Intern Med* 2011;171(10):929-935. PMID: PMC3634672.
273. Hochman JS, Reynolds HR, Dzavik V, Buller CE, Ruzyllo W, Sadowski ZP, Maggioni AP, Carvalho AC, Rankin JM, White HD, Goldberg S, Forman SA, Mark DB, Lamas GA; for the Occluded Artery Trial Investigators. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. *Circulation* 2011;124(21):2320-2328. PMID: PMC3235739.
274. Chin CT, Wang TY, Anstrom KJ, Zhu B, Maa JF, Messenger JF, Ryan KA, Davison-Ray L, Zettler M, Effron MB, Mark DB, Peterson ED. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. *Am Heart J* 2011;162(1):81-87.

275. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). *Am Heart J* 2012;163(1):7-12. PMID: PMC3243954.
276. Reynolds HR, Forman SA, Tamis-Holland JE, Steg PG, Mark DB, Pearte CA, Carvalho AC, Sopko G, Liu L, Lamas GA, Kruk M, Lobo-Grudzien K, Ruzyllo W, Hochman JS. Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: Analysis of the Occluded Artery Trial (OAT). *Am Heart J* 2012;163:462-469. PMID: PMC3308117.
277. Mudrick D, Kaltenbach LA, Shah B, Lytle B, Masoudi FA, Mark DB, Federspiel JJ, Cowper PA, Green C, Douglas PS. Downstream testing and subsequent procedures after coronary computed tomographic angiography following coronary stenting in patients  $\geq 65$  years of age. *Am J Cardiol* 2012;110(6):776-783. PMID: PMC3915770.
278. Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB, McDaniel G, Pressler SJ, Schron E, Wang P, Zeigler VL; on behalf of the American Heart Association Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Cardiovascular Disease in the Young. Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter defibrillators and their families: a scientific statement from the American Heart Association. *Circulation*.2012;126;2146-2172.
279. Finlen Copeland CA, Vock DM, Pieper K, Mark DB, Palmer SM. Impact of lung transplantation upon recipient quality of life: a serial, prospective, multi-center analysis through the first posttransplant year. *Chest* 2013;143(3):744-750. PMID: PMC3747721.
280. Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. *JAMA* 2013;309(1):55-62. PMID: PMC3638257.
281. Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Al Hallstrom PD, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, Sanders GD. Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. *Heart Rhythm* 2013;10(6):828-835. PMID: PMC4037291.
282. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL, for the TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction. *JAMA* 2013;309(12):1241-1250. PMID: PMC4066975.

283. Chen J, Johnson G, Hellkamp AS, Anderson J, Mark DB, Lee KL, Bardy GH, Poole JE. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). *J Am Coll Cardiol* 2013;61:2161-2168. PMID: PMC3760407.
284. Aoukar PS, Poole JE, Johnson GW, Anderson J, Hellkamp AS, Mark DB, Lee KL, Bardy GH. No benefit of dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial. *Heart Rhythm* 2013;10:970-976.
285. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Johnson GW, Poole JE, Lee KL, Bardy GH. Thyroid function in heart failure and impact on mortality. *JACC Heart Fail*. 2013;1(1):48-55. PMID: PMC3803999.
286. Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). *Circ Cardiovasc Qual Outcomes*. 2014;7(1):15-24. PMID: PMC4111470.
287. Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL, for the TACT (Trial to Assess Chelation Therapy) Investigators. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. *Ann Intern Med*. 2013;159(12):797-804. PMID: PMC4143134.
288. Ahmad T, Fiuzat M, Mark DB, Neely B, Neely M, Kraus WE, Kitzman DW, Whellan DJ, Donahue M, Zannad F, Pina IL, Adams K, O'Connor CM, Felker GM. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. *Am Heart J*. 2014;167(2):193-202. PMID: PMC3899586.
289. Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders GD. Do patients with left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? *Int J Cardiol*. 2014;172(1):253-254.
290. Wang TY, McCoy L, Henry TD, Effron MB, Messenger JC, Cohen DJ, Mark DB, Stone GW, Zettler M, Singh M, Fonarow GC, Peterson ED; TRANSLATE-ACS Study Investigators. Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. *J Am Coll Cardiol*. 2014;63(16):1700-1702.
291. Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, Sanders GD. Implantable cardioverter-defibrillators for

- primary prevention of Sudden Cardiac Death in CKD: A meta-analysis of patient-level data from 3 randomized trials. *Am J Kidney Dis.* 2014; 64(1):32-39.
292. Mark DB, Anderson JL, Brinker JA, Brophy JA, Casey DE Jr, Cross RR, Edmundowicz D, Hachamovitch R, Hlatky MA, Jacobs JE, Jaskie S, Kett KG, Malhotra V, Masoudi FA, McConnell MV, Rubin GD, Shaw LJ, Stanko S, Ward RP. ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 health policy statement on use of noninvasive cardiovascular imaging: a report of the American College of Cardiology Clinical Quality Committee. *J Am Coll Cardiol.* 2014;63(7):698-721.
293. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measure and Task Force on Practice Guidelines. *Circulation* 2014;129:2329-2345. *J Am Coll Cardiol* 2014;63(21):2304-2322.
294. Fishbein DP, Hellkamp AS, Mark DB, Walsh MN, Poole JE, Anderson J, Johnson G, Lee KL, Bardy GH, SCD-HeFT Investigators. Use of the six-minute walk distance to identify variations in treatment benefits from ICD and amiodarone: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *J Am Coll Cardiol* 2014;63(23):2560-2568.
295. Patton KK, Hellkamp AS, Lee KL, Mark DB, Johnson GW, Anderson J, Bardy GH, Poole JE. Unexpected deviation in circadian variation of ventricular arrhythmias in the Sudden Cardiac Death in Heart Failure Trial. *J Am Coll Cardiol* 2014;63(24):2702-2708. PMID: PMC4065626.
296. Al-Khatib SM, Hellkamp AS, Fonarow GC, Mark DB, Curtis LH, Hernandez A, Anstrom KJ, Peterson ED, Sanders GD, Al-Khalidi HR, Hammill BG, Heidenreich PA, Hammill S. Association between prophylactic implantable cardioverter defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. *JAMA* 2014;311(21):2209-2015. PMID: PMC4122230.
297. Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, Cooper L; PROMISE investigators. PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. *Am Heart J* 2014;167(6):796-803. PMID: PMC4044617.
298. Lamas GA, Boineau R, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee LK. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the Trial to Assess Chelation Therapy. *Am Heart J* 2014;168(1):37-44. PMID: PMC4069605.

299. Mark DB, Anstrom KJ, Clapp-Channing NE, Knight JD, Boineau R, Goertz R, Rozema TC, Liu DM, Nahin RL, Rosenberg Y, Drisko J, Lee KL, Lamas GA, of the TACT Investigators. Quality of life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the Trial to Assess Chelation Therapy randomized trial. *Circ Cardiovasc Qual Outcomes* 2014;7:508-516. PMID: PMC4146707.
300. Stewart RAH, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JGF, Pina IL, Velazquez EJ, Rynkiewicz A, White H. Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). *JCHF* 2014;2(4):335. PMID: PMC4127151.
301. Goehler A, McMahan PM, Lumish HS, Wu C, Munshi V, Gilmore M, Chung JH, Ghoshhajra BB, Mark D, Truong QA, Gazelle GS, Hoffman U. Cost-effectiveness of follow-up pulmonary nodules incidentally detected on cardiac CT angiography in patients with suspected coronary artery disease. *Circulation* 2014;130(8):668-675. PMID: PMC41399449.
302. Felker GM, Ahmad T, Anstrom KJ, Adams KF, Cooper LS, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Leifner ES, Mark DB, Desvigne-Nickens P, Paynter G, Pina IL, Wellan DJ, O'Connor CM. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. *JCHF* 2014;2(5):457-465. PMID: PMC4194159.
303. Mark DB, Knight JD, Velazquez EJ, Wasilewski J, Howlett JG, Smith PK, Spertus JA, Rajda M, Yadav R, Hamman BL, Malinowski M, Naik A, Rankin G, Harding TM, Drew LA, Desvigne-Nickens P, Anstrom KJ. Quality-of-life outcomes with coronary artery bypass surgery in ischemic left ventricular dysfunction: a randomized trial. *Ann Intern Med* 2014;161(6):392-399. PMID: PMC4182862.
304. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. *JACC Heart Fail* 2014;2(6):623-629. PMID: PMC4256119.
305. Al-Khatib SM, Daubert JP, Anstrom KJ, Daoud EG, Gonzalez M, Saba S, Jackson KP, Reece T, Gu J, Pokorney SD, Granger CB, Hess PL, Mark DB, Stevenson WG. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. *J Cardiovasc Electrophysiol* 2014;26(2):151-157.
306. Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin L, Cannon CP, Harrington RA, Mark DB. Economic analysis of

- ticagrelor therapy from a U.S. perspective: results from the Study of Platelet Inhibition and Patient Outcomes (PLATO). *JACC* 2015;65(5):465-476.
307. Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, Sanders GD, Al-Khatib SM. Primary prevention implantable cardioverter-defibrillators and survival in older women. *JACC Heart Fail* 2014;3(2):159-167. PMID: PMC4461749.
  308. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudencuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LYT, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. *Circ Cardiovasc Qual Outcomes* 2015;8(2):179-186. PMID: PMC4408540.
  309. Douglas PS, Hoffman U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL; PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med* 2015;372(14):1291-1300. PMID: PMC4473773.
  310. Hess CN, Krucoff MW, Sheng S, Anstrom KJ, Barham WB, Gilchrist IC, Harrington RA, Jacobs AK, Mehran R, Messenger JC, Mark DB, Rao SV. Comparison of quality of life measures after radial versus femoral artery access for cardiac catheterization in women: results from the SAFE-PCI for Women Quality of Life Substudy. *Am Heart J* 2015;170(2):371-379.
  311. Au-Yeung WM, Reinhall P, Poole JE, Anderson J, Johnson G, Fletcher RD, Moore HJ, Mark DB, Lee KL, Bardy GH. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. *Heart Rhythm* 2015;12:2058-2066.
  312. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. *Circulation* 2016;133(1):39-47.
  313. Krishnamoorthy A, Peterson ED, Knight JD, Anstrom KJ, Effron MB, Zettler ME, Davidson-Ray L, Baker BA, McCollam PL, Mark DB, Wang TY. How reliable are patient-reported rehospitalizations? Implications for the design of future practical clinical studies. *J Am Heart Assoc* 2016;5(1):pii:e002695. PMID: PMC4859389.
  314. Mark DB. Assessing quality of life outcomes in cardiovascular clinical research. *Nat Rev Cardiol* 2016;13(5):286-308.



315. Alexander KP, Stadnyuk O, Arnold SV, Mark DB, Ohman EM, Anstrom KJ. Assessing quality of life and medical care in chronic angina using an internet survey. *Interact J Med Res* 2016;5(2):e12. PMID: PMC4865655.
316. Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, Hoffman U, Litwin SE, Daubert MA, Shah SH, Ariani K, Bullock-Palmer RP, Martinez B, Lee KL, Douglas PS. Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease: insights from the PROMISE trial. *JACC Cardiovasc Imaging* 2016;9(4):337-46. PMID: PMC4982809.
317. Pagidipati NJ, Hemal K, Coles A, Mark DB, Dolor RJ, Pellikka PA, Hoffmann U, Litwin SE, Udelson J, Daubert MA, Shah SH, Martinez B, Lee KL, Douglas PS. Sex differences in functional stress test versus CT angiography in symptomatic patients with suspected CAD: Insights from PROMISE. *J Am Coll Cardiol* 2016;67(22):2607-16. PMID: PMC4892993.
318. Mark DB, Anstrom KJ, Sheng S, Baloch KN, Daniels MR, Hoffmann U, Patel MR, Cooper LS, Lee KL, Douglas PS on behalf of the PROMISE Investigators. Quality of life outcomes with anatomic versus functional diagnostic testing strategies in symptomatic patients with suspected coronary artery disease: results from the PROMISE randomized trial. *Circulation* 2016;133(21):1995-2007. PMID: PMC4879021.
319. Lamas GA, Navas-Acien A, Mark DB, Lee KL. Heavy metals, cardiovascular disease, and the unexpected benefits of chelation therapy. *J Am Coll Cardiol* 2016;67(20):2411-8. PMID: PMC4876980.
320. Mark DB, Federspiel JJ, Cowper PA, Anstrom KJ, Hoffmann U, Patel MR, Davidson-Ray L, Daniels MR, Cooper LS, Knight JD, Lee KL, Douglas PS, on behalf of the PROMISE Investigators. Economic outcomes with anatomic versus functional diagnostic testing for coronary artery disease. *Ann Intern Med* 2016;165(2):94-102. PMID: PMC5046832.
321. Kaul P, Ohman EM, Knight JD, Anstrom KJ, Roe MT, Boden WE, Hochman JS, Gasparovic V, Armstrong PW, McCollam P, Fakhouri W, Cowper PA, Davidson-Ray L, Clapp-Channing NE, White HD, Fox KAA, Prabhakaran D, Mark DB. Health-related quality-of-life outcomes with prasugrel among medically managed Non-ST elevation acute coronary syndrome patients: insights from the TRILOGY ACS trial. *Am Heart J* 2016;178:55-64.
322. Ladapo JA, Lee KL, Coles A, Huang M, Mark DB, Dolor RJ, Pelberg RA, Budoff M, Sigurdsson G, Severance HW, Douglas PS. Changes in medical therapy and lifestyle after anatomical or functional testing for coronary artery disease. *JAHA* 2016;5 (10):e003807. PMID: PMC5121482.
323. Mark DB, Lee KL, Harrell FE. Understanding the role of p values and hypothesis tests in clinical research. *JAMA Cardiol* 2016;1(9):1048-1054.

324. Shah R, Yow E, Jones WS, Kohl LP 3<sup>rd</sup>, Kosinski AS, Hoffman U, Lee KL, Fordyce CB, Mark DB, Lowe A, Douglas PS, Patel MR. Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. *Am Heart J* 2017;184:1-9.
325. Fordyce CB, Douglas PS, Roberts RS, Hoffman U, Al-Khlaidid HR, Patel MR, Granger CB, Kostis J, Mark DB, Lee KL, Udelson JE; Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Investigators. Identification of patients with stable chest pain deriving minimal value from noninvasive testing: the PROMISE minimal-risk tool, a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 2017;2(4):400-408. PMID: PMC5470411.
326. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LY, Mark DB, Lee KL, Kadish A, Bardy GH, Sanders GD. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis. *JAMA Cardiol* 2017;2(6):685-688.
327. Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJ, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial. *JAMA Cardiol* 2017;2(5):525-534.
328. Hoffman U, Ferencik M, Udelson JE, Picard MH, Truong QA, Patel MR, Huang M, Pencina MJ, Mark DB, Heitner JF, Fordyce CB, Pellikka PA, Tardif JC, Budoff MJ, Nahhas G, Chow BJ, Kosinski AS, Lee KL, Douglas PS; PROMISE Investigators. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial. *Circulation* 2017;135(24):2320-2332.
329. Lu MT, Ferencik M, Roberts RS, Lee KL, Ivanov A, Adami E, Mark DB, Jaffer FA, Leipsic JA, Douglas PS, Hoffman U. Noninvasive FFR derived from coronary CT angiography: management and outcomes in the PROMISE trial. *JACC CV Imaging* 2017;10(11):1350-1358. PMID: PMC5632098.
330. Fanaroff AC, James SK, Weisz G, Prather K, Anstrom KJ, Mark DB, Ben-Yehuda O, Alexander KP, Stone GW, Ohman EM. Ranolazine after incomplete percutaneous coronary revascularization in patients with versus without diabetes mellitus: RIVER-PCI trial. *J Am Coll Cardiol* 2017;69(18):2304-2313.
331. Pokharel Y, Chinnakondepalli K, Vilain K, Wang K, Mark DB, Davis G, Blazing MA, Giugliano RP, Braunwald E, Cannon CP, Cohen DJ, Magnuson EA. Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *Circ Cardiovasc Qual Outcomes* 2017;10(5). pii: e003201.

332. Gulmaraes PO, Krishnamoorthy A, Kaltenbach LA, Anstrom KJ, Effron MB, Mark DB, McCollam PL, Davidson-Ray L, Peterson ED, Wang TY. Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary analysis of the TRANSLATE-ACS study. *JAMA Cardiol* 2017;2(7):750-757.
333. Genders TSS, Coles A, Hoffmann U, Patel MR, Mark DB, Lee KL, Steyerberg EW, Hunink MGM, Douglas PS, CAD Consortium and PROMISE Investigators. The external validity of prediction models for the diagnosis of obstructive coronary artery disease in patients with stable chest pain: insights from the PROMISE trial. *JACC Cardiovasc Imaging* 2017; epub ahead of print.
334. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, Adams PA, Speck A, Johnson KS, Krishnamoorthy A, Yang H, Anstrom KJ, Dodson GC, Taylor DH Jr, Kirchner JL, Mark DB, O'Connor CM, Tulskey JA. Palliative care in heart failure: the PAL-HF randomized controlled clinical trial. *J Am Coll Cardiol* 2017;70(3):331-341. PMID: PMC5664956.
335. Zeitler EP, Al-Khatib SM, Friedman DJ, Han JY, Poole JE, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, Sanders GD. Predicting appropriate shocks in patients with heart failure: patient level meta-analysis from SCD-HeFT and MADIT II. *J Cardiovasc Electrophysiol* 2017;28(11):1345-1351.
336. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Leifer ES, Desvigne-Nickens P, O'Connor CM. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2017;318(8):713-720. PMID: PMC5605776.
337. Hess PL, Al-Khalidi HR, Friedman DJ, Mulder H, Kucharska-Newton A, Rosamond WR, Lopes RD, Gersh BJ, Mark DB, Curtis LH, Post WS, Prineas RJ, Sotoodehnia N, Al-Khatib SM. The metabolic syndrome and risk of sudden cardiac death: the atherosclerosis risk in communities study. *J Am Heart Assoc* 2017;6(8):pii:e006103. PMID: PMC5586451.
338. Lu MT, Douglas PS, Udelson JE, Adami E, Ghoshhajra BB, Picard MH, Roberts R, Lee KL, Einstein AJ, Mark DB, Velazquez EJ, Carter W, Ridner M, Al-Khalidi HR, Hoffmann U. Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: a randomized comparison of test complications, incidental findings, and radiation dose. *J Cardiovasc Comput Tomogr* 2017;11(5):373-382.
339. Friedman DJ, Al-Khatib SM, Zeitler EP, Han J, Bardy GH, Poole JE, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, Sanders GD. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: a pooled analysis of 4 randomized controlled trials. *Am Heart J* 2017;191:21-29. PMID: PMC5657554.

340. Sharma A, Sekaran NK, Coles A, Pagidipati NJ, Hoffmann U, Mark DB, Lee KL, Al-Khalidi HR, Lu MT, Pellikka PA, Trong QA, Douglas PS. Impact of diabetes mellitus on the evaluation of stable chest pain patients: insights from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial. *J Am Heart Assoc* 2017;6(11). pii: e007019. PMID: PMC5721780.
341. da Silva KR, Costa R, Rodrigues CG, Schasechter A, Nobre MC, Passman R, Mark DB. Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials. *Eur J Cardiovasc Nurs* 2017;1474515117739619. [epub ahead of print]
342. Ladapo JA, Coles A, Dolor RJ, Mark DB, Cooper L, Lee KL, Goldberg J, Shapiro MD, Hoffmann U, Douglas PS. Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America. *BMJ Open* 2017;7(9):e016364. PMID: PMC5640109.
343. Sze E, Dunning A, Loring Z, Atwater BD, Chiswell K, Daubert JP, Kisslo JA, Mark DB, Velazquez EJ, Samad Z. Comparison of incidence of left ventricular systolic dysfunction among patients with left bundle branch block versus those with normal QRS duration. *Am J Cardiol* 2017;120(11):1990-1997.
344. Issa OM, Roberts R, Mark DB, Boineau R, Goertz C, Rosenberg Y, Lewis EF, Guarneri E, Drisko J, Magaziner A, Lee KL, Lamas GA. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). *Am Heart J* 2018;195:70-77.
345. Ferencik M, Mayrhofer T, Bittner DO, Emami H, Puchner SB, Lu MT, Meyersohn NM, Ivanov AV, Adami EC, Patel MR, Mark DB, Udelson JE, Lee KL, Douglas PS, Hoffmann U. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. *JAMA Cardiol* 2018;3(2):144-152.

## EDITORIALS

1. Blumenthal JA, Mark DB. Quality of life and recovery after cardiac surgery. *Psychosom Med* 1994;56:213-215.
2. Mark DB. Treatment of myocardial infarction in the post-GUSTO era: A U.S. perspective. *Pharmacoeconomics* 1996;9(6):473-477.

3. Eisenstein EL, Mark DB, Califf RM. Importance of cost and quality of life in decisions about routine angiography after acute MI: the role of cost effectiveness models. *Circulation* 1996;94(5):869-871.
4. Alexander KP, Mark DB. Effect of gender on angioplasty outcome: are we closer to the answer? *Mayo Clinic Proceedings* 1997;72:89-91.
5. Jollis JG, Mark DB. Quality improvement and clinical research: an important partnership. *Am J Mgd Care* 1997;3:1225-1226.
6. Califf RM, Mark DB. Our vision for the American Heart Journal. *Am Heart J* 1997;133:137-8.
7. Newby LK, Mark DB. The chest pain unit: ready for prime time? *N Engl J Med* 1998;339:1930-1932.
8. Califf RM, Mark DB. Dealing with success at the American Heart Journal. *Am Heart J* 1999;137:769.
9. Mark DB. Sex bias in cardiovascular care: should women be treated more like men? *JAMA* 2000;283(5):659-661.
10. Newby LK, Mark DB. Navigating the scylla and charybdis of chest pain management in the emergency department. Is a computer the answer? *Am J Med* 2002;112:154-156.
11. Mark DB, Lee TH. Conservative management of acute coronary syndrome: cheaper and better for you? *Circulation* 2002;105:666-668.
12. Mark DB, Newman MF. Protecting the brain in coronary artery bypass graft surgery. *JAMA* 2002;287(11):1448-50.
13. Kandzari DE, Mark DB. Intracoronary brachytherapy: time to sell short? *Circulation* 2002;106:646-648.
14. Liao L, Mark DB. Clinical prediction models: are we building better mousetraps? *J Am Coll Cardiol* 2003;42(5):851-853.
15. Whellan DJ, Mark DB. Quality still doesn't pay in heart failure management. *J Card Fail* 2003;9(4):263-265.
16. Mark DB, Lauer MS. Exercise capacity: the prognostic variable that doesn't get enough respect. *Circulation* 2003;108:1534-1536.
17. Mark DB, Newby LK. Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible? *Eur Heart J* 2003;24(18):1613-1615.

18. Mark DB, Felker GM. BNP: a biomarker for all seasons? *N Engl J Med* 2004;350(7):718-720.
19. Peterson ED, Mark DB. Off-pump bypass surgery—ready for the big dance? *JAMA* 2004;291:1897-1899.
20. Kong DF, Mark DB. Economic impact of new interventional therapies: are we asking the right questions? *J Am Coll Cardiol* 2004;44(9):1809-1811.
21. Newman MF, Blumenthal JA, Mark DB. Fixing the heart: must the brain pay the price? *Circulation* 2004;110: 3402:-3403.
22. Hlatky MA, Mark DB. The high cost of implantable defibrillators. *Eur Heart J* 2007;28(4):388-391.
23. Mark DB. Percutaneous coronary revascularization: is it ever worth what it costs? *Heart* 2007;93:1161-1163.
24. Mark DB, Hodgson P, Califf RM. What we publish in the American Heart Journal and why. *Am Heart J* 2007;154:1-2.
25. Mark DB. Interpreting the music of drug-eluting stents: halcyon song or albatross dirge? *J Am Coll Cardiol* 2008;51:1854-1856.
26. Mark DB. Has American Heart Journal gone to the blogs? *Am Heart J* 2009;157:955-956.
27. Mark DB, Kong DF. Cardiac computed tomographic angiography: what's the prognosis? *J Am Coll Cardiol* 2010;55:1029-1031.
28. Mark DB, Patel MR, Anstrom KJ. Trade-offs and toss-ups making revascularization decisions in carotid artery disease. *J Am Coll Cardiol* 2011;58:1566-1568.
29. Mark DB, Mentz RJ. The Placement of Aortic Transcatheter Valve (PARTNER) Trial: a health economic and policy perspective. *Circulation* 2012;125(25):3243-3245.
30. Mark DB, Hodgson P, Anuels J, Califf RM. Transitions at the American Heart Journal. *Am Heart J* 2015;169(4):445.
31. Mark DB, O'Connor CM. When business and science clash, how can we avoid harming patients? The case of AVOID-HF. *J Am Coll Cardiol HF* 2016;4(2):106-108.
32. Pokorney SD, Mark DB. Cost-effectiveness of left atrial appendage occlusion: a case based on facts not in evidence? *Circ Arrhythm Electrophysiol* 2016;9(6).

33. Mark DB, Hansen SM, Starks ML, Cummings ML. Drone-based automatic external defibrillators for sudden death? Do we need more courage or more serenity? *Circulation* 2017;135(25):2466-2469.
34. Califf RM, McCall J, Mark DB. Cosmetics, regulations, and the public health: understanding the safety of medical and other products. *JAMA Intern Med* 2017;177(8):1080-1082.
35. Mark DB, Schulman KA. PCSK9 inhibitors and the choice between innovation, efficiency, and affordability. *JAMA* 2017;318(8):711-712.
36. Mark DB, Richman I, Hlatky MA. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy – breakthrough in low-density lipoprotein cholesterol lowering, breakdown in value. *JAMA Cardiol* 2017;2(10):1066-1068.
37. Mark DB, Patel MR. Patient-reported outcomes in revascularization decisions for left main disease: sharing the EXCELlence. *J Am Coll Cardiol* 2017;70(25):3123-3126.

#### **BOOKS AND BOOK CHAPTERS**

1. Mark DB, Califf RM, Stack RS, Phillips HR: Cardiac catheterization. In: Sabiston DC (ed): *The Davis - Christopher Textbook of Surgery*, 13th ed. Philadelphia: W.B. Saunders Company, 1986;2135-2165.
2. Kisslo J, Adams D, Mark DB: An introduction to Doppler. *Clinics in Diagnostic Ultrasound* 1986;17:1-6.
3. Mark DB, Adams D, Kisslo J: The Doppler principle and the study of cardiac flows. *Clinics in Diagnostic Ultrasound* 1986;17:7-23.
4. Kisslo J, Mark DB, Adams D: Pulsed and continuous wave Doppler. *Clinics in Diagnostic Ultrasound* 1986;17:25-46.
5. Adams D, Mark DB, Kisslo J: Use of the Doppler controls. *Clinics in Diagnostic Ultrasound* 1986;17:47-62.
6. Adams D, Mark DB, Kisslo J: The Doppler examination. *Clinics in Diagnostic Ultrasound* 1986; 17:63-89.
7. Mark DB, Robertson JH, Adams D, Kisslo J: Doppler evaluation of valvular regurgitation. *Clinics in Diagnostic Ultrasound* 1986;17:91-122.
8. Kisslo J, Krafchek J, Adams D, Mark DB: Doppler evaluation of valvular stenosis. *Clinics in Diagnostic Ultrasound* 1986;17:123-145.

9. Kisslo J, Adams D, Mark DB (editors): Basic Doppler Echocardiography. Clinics in Diagnostic Ultrasound. New York, Churchill Livingstone, 1986.
10. Cheney ML, Mark DB: Medico-legal principles of emergency and intensive medical care. In: Califf RM, Wagner GS (eds): Acute Coronary Care 1987. Boston: Martinus Nijhoff Publishing, 1987;37-48.
11. Cobb FR, Higginbotham MB, Mark DB: Diagnosis of coronary disease in the elderly. In: Wenger NK, Furburg CD, Pitt E (eds): Coronary Heart Disease in the Elderly. New York: Elsevier Science Publishing Company, 1986:303-319.
12. Pryor DB, Harrell FE Jr., Rankin JS, Lee KL, Muhlbaier LH, Hlatky MA, Mark DB, Oldham HN, Reves JG, Califf RM. Trends in the presentation, management and survival of patients with coronary artery disease: The Duke Database for Cardiovascular Disease. In: Higgins M, Luepker RV, (eds.): Trends in Coronary Heart Disease Mortality: The Influence of Medical Care. New York: Oxford University Press 1988;76-87.
13. Hlatky MA, Mark DB. Overview of assessment of laboratory tests during acute MI. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers 1988;91-99.
14. O'Connor CM, Mark DB, Califf RM. Combined thrombolysis and angioplasty in acute myocardial infarction: clinical results. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers 1988:331-346.
15. Califf RM, Mark DB, Topol EJ. Randomized trials of acute coronary intervention. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers 1988:347-363.
16. Mark DB, Dunham G, Califf RM. Therapeutic drug monitoring in the acutely ill cardiac patient. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers 1988;492-507.
17. Mark DB, Hlatky MA, Pryor DB. The exercise treadmill test in patients recovering from an acute myocardial infarction. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers 1988;573-591.
18. Califf RM, Mark DB, Wagner GS (eds). Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers 1988.
19. Califf RM, Ohman EM, Frid DJ, Fortin DF, Mark DB, Hlatky MA, Herndon JE, Bengtson JR. Restenosis: the clinical issues. In: Topol EJ (ed.): Textbook of Interventional Cardiology. Philadelphia: W.B. Saunders Company, 1990:363-394.



20. Buller C, Mark D, Phillips H, Stack RS. Cardiac catheterization and percutaneous coronary angioplasty. In: Sabiston DC (ed): *The Davis-Christopher Textbook of Surgery*, 14th ed. Philadelphia: W.B. Saunders Company 1991:1826-1843.
21. Mark DB. Ischemic heart disease. In: Conn RB (ed.): *Current Diagnosis 8*. Philadelphia: W.B. Saunders Company 1991:416-427.
22. Hlatky MA, Mark DB. Angina pectoris. In: Dornbrand L, Hoole AJ, Pickard CG (eds): *Manual of Clinical Problems in Adult Ambulatory Care Medicine*. Boston: Little Brown and Company 1992:126-133.
23. Mark DB, Jollis J. Economic aspects of therapy for acute myocardial infarction. In: Bates ER (ed.): *Thrombolysis and Adjunctive Therapy for Acute Myocardial Infarction*. New York: Marcel Dekker, Inc. 1992:471-496.
24. Mark DB, Pryor DB. Risk screening and exercise testing in women. In: Wenger NK, Speroff L (eds): *Cardiovascular Health and Disease in Women. Proceedings of an NHLBI Conference*. Greenwich, Conn: Le Jaq 1993:81-90.
25. Cheney ML, Mark DB. Medicolegal issues. In: Topol EJ (ed): *Textbook of Interventional Cardiology*, 2nd ed. Philadelphia: W.B. Saunders Company 1993:1372-1391.
26. Mark DB. Medical economics and health policy issues for interventional cardiology. In Topol EJ (ed): *Textbook of Interventional Cardiology*, 2nd ed. Philadelphia: W.B. Saunders Company 1993:1323-1353.
27. Mark DB. Assessment of prognosis in patients with coronary artery disease. In Roubin GS, Califf RM, O'Neill WW, Stack RS, Phillips HR III (eds.): *Interventional Cardiovascular Medicine: Principles and Practice*. New York: Churchill Livingstone, Inc. 1994:165-185.
28. Charles ED, Mark DB. The economics of percutaneous intervention. In Roubin GS, Califf RM, O'Neill WW, Stack RS, Phillips HR III (eds.): *Interventional Cardiovascular Medicine: Principles and Practice*. New York. Churchill Livingstone, Inc. 1994:373-384.
29. Califf RM, Nelson CL, Mark DB. Using a clinical database for quality assurance and clinical research. In Roubin GS, Califf RM, O'Neill WW, Stack RS, Phillips HR III (eds.): *Interventional Cardiovascular Medicine: Principles and Practice*. New York. Churchill Livingstone, Inc. 1994:951-957.
30. Mark DB. Quality of life assessment. In: Califf RM, Mark DB, Wagner GS (eds): *Acute Coronary Care*. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:183-199.

31. Mark DB. Economic analysis methods and endpoints. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:167-182.
32. Harrington RA, Califf RM, Phillips HR, Mark DB. Primary angioplasty for acute myocardial infarction. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:305-313.
33. Mark DB, Dunham G. Therapeutic drug monitoring in the acutely ill patient. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:481-488.
34. Mark DB, Jones RH. The National Clinical Practice Guidelines for Unstable Angina. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:503-523.
35. Mark DB, Froelicher VF. Exercise treadmill testing and ambulatory monitoring. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:767-779.
36. Califf RM, Bartrug B, Rogers MC, Roth D, Bride W, Fitzpatrick K, Mark DB. Developing a rational system to contain costs on the cardiac care unit. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:895-912.
37. Cheney ML, Mark DB. Medicolegal issues. In: Califf RM, Mark DB, Wagner GS (eds): Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995:913-922.
38. Califf RM, Mark DB, Wagner GS (eds). Acute Coronary Care. 2nd ed. St. Louis: Mosby-Year Book, Inc. 1995.
39. Mark DB. Economics of acute myocardial infarction. In: Califf RM (ed): Acute Myocardial Infarction and Other Ischemic Syndromes, Volume VIII. In: Braunwald E (ed): The Atlas of Heart Diseases. Philadelphia: Current Medicine 1996:15.1-15.15.
40. Mark DB. Multivessel disease. In: Ellis SG, Holmes Jr. DR (eds): Strategic Approaches in Coronary Intervention. Baltimore: Williams & Wilkins 1995:502-518.
41. Mark DB, Braunwald E. Medical management of unstable angina. In Fuster V, Ross R, Topol EJ (eds): Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven Press 1996:1315-1326.
42. Califf RM, Mark DB. Unstable angina: clinical presentation and diagnostic techniques. In Fuster V, Ross R, Topol EJ (eds): Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven Press. 1996:1299-1314.

43. Siegler IC, Kaplan BH, VonDras DD, Mark DB. Cardiovascular health: a challenge for midlife. In Willis S, Reid J (eds): Middle Aging: Development in the Third Quarter of Life. Orlando: Academic Press 1998:147-157.
44. Mark DB, Topol EJ. Chronic coronary artery disease. In Talley JD (ed): Cost Effective Diagnosis and Treatment of Coronary Artery Disease. Baltimore: Williams & Wilkins. 1997:168-177.
45. Eisenstein EL, Mark DB. Economic issues related to diagnosis and therapy for coronary heart disease. In Pepine CJ (ed): Diagnostic and Therapeutic Cardiac Catheterization. Baltimore: Williams & Wilkins. 1998:892-913.
46. Mark DB. Medical economics in cardiovascular medicine. In Topol EJ (ed): Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven. 1997:1033-1061.
47. Hlatky MA, Mark DB, Stettin GD. Angina pectoris. In Dornbrand L, Hoole AJ and Fletcher RH (eds): Manual of Clinical Problems in Adult Ambulatory Care, 3rd edition. Philadelphia: Lippincott-Raven. 1997:133-141.
48. Tung CY, Mark DB. Cost effectiveness of prevention of cardiac disease. In Yusuf S, Cairns J, Camm J, Fallen E, Gersh B (eds): Evidence Based Medicine. London: BMJ Books. 1998:303-314.
49. Cheney ML, Mark DB. Medicolegal issues. In Topol EJ (ed): Textbook of Interventional Cardiology, 3<sup>rd</sup> Edition. Philadelphia: W.B. Saunders Company. 1998:929-943.
50. Mark DB. Assessment of prognosis in patients with coronary artery disease. In Stack RS (ed): Interventional Cardiovascular Medicine: Principles and Practice, 2<sup>nd</sup> Edition. New York: Churchill-Livingstone. 2002:161-182.
51. Mark DB. Medical economics for interventional cardiology. In Topol EJ (ed): Textbook of Interventional Cardiology, 3<sup>rd</sup> Edition. Philadelphia: W.B. Saunders Company. 1998:889-909.
52. Mark DB. Economics of glycoprotein IIb/IIIa inhibitor. In Lincoff AM (ed): Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ: Humana Press. 1999:253-266.
53. Mark DB. Angina and unstable angina. In Wachter R, Goldman L, Hollander H (eds): Hospital Medicine. Baltimore: Williams & Wilkins. 1999:203-216.
54. Jollis JG, Mark DB. Multivessel disease. In Ellis SG, Holmes DR (eds): Strategic Approaches in Coronary Intervention, 2<sup>nd</sup> Edition. Baltimore: Williams & Wilkins. 1999:413-429.

55. Mark DB. Decision making in clinical medicine. In Braunwald E (ed): Harrison's Principles of Internal Medicine, 15<sup>th</sup> Edition. New York: McGraw Hill. 2001:8-14.
56. Mark DB. Economic issues in clinical medicine. In Braunwald E (ed): Harrison's Principles of Internal Medicine, 15<sup>th</sup> Edition. New York: McGraw Hill. 2001:14-19.
57. Hlatky MA, Mark DB. Economics and cardiovascular disease. In Braunwald E, Zipes DP, Libby P (eds): Heart Disease, 6<sup>th</sup> Edition. Philadelphia: W.B. Saunders Company. 2001:19-26.
58. Mark DB. Economics of acute myocardial infarction. In: Califf RM (ed): Acute Myocardial Infarction and Other Ischemic Syndromes, Volume IX. In: Braunwald E (ed): The Atlas of Heart Diseases. Philadelphia: Current Medicine. 2003.
59. Eisenstein EL, Mark DB. Cost effectiveness and new diagnostics and therapies for ACS. In: Topol EJ (ed): Acute Coronary Syndromes, 2<sup>nd</sup> Edition. New York: Marcel Dekker, Inc. 2001:811-844.
60. Mark DB. Angina and unstable angina. In Wachter R, Goldman L, Hollander H (eds): Hospital Medicine, 2<sup>nd</sup> Edition. Baltimore: Williams & Wilkins. 2003.
61. Mark DB. Medical economics in cardiovascular medicine. In Topol EJ (ed): Textbook of Cardiovascular Medicine, 2<sup>nd</sup> Edition. Philadelphia: Lippincott Williams & Wilkins. 2002:957-979.
62. Mark DB. Cost effectiveness of prevention of cardiac disease. In Yusuf S, Cairns J, Camm J, Fallen E, Gersh B (eds): Evidence Based Medicine. London: BMJ Books. 2002:300-308.
63. Mark DB. Medical economics for interventional cardiology. In Topol EJ (ed): Textbook of Interventional Cardiology, 4<sup>th</sup> Edition. Philadelphia: W.B. Saunders Company. 2002:999-1019.
64. Mark DB. Economics of therapy for acute coronary syndromes. In Weintraub WS (ed): Cardiovascular Health Care Economics. Totowa, NJ: The Humana Press. 2003:173-185.
65. Bardy GH, Lee KL, Mark DB, Poole JE, Fishbein DP and the SCD-HeFT Investigators. Sudden cardiac death—heart failure trial (SCD-HeFT). In Woosley, RL and Singh, SN (eds): Arrhythmia Treatment and Therapy. New York, NY: Marcel Dekker, Inc. 2000;323-342.
66. Mark DB. Economics of glycoprotein IIb/IIIa inhibitor. In Lincoff AM (ed): Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, 2<sup>nd</sup> Edition. Totowa, NJ: Humana Press. 2002:305-319.

67. Mark DB. Decision-making in clinical medicine. In Braunwald E (ed): Harrison's Principles of Internal Medicine, 16<sup>th</sup> Edition. New York, NY: McGraw-Hill 2005:6-13.
68. Hlatky MA, Mark DB. Economics and cardiovascular disease. In Braunwald E, Zipes DP, Libby P (eds): Heart Disease, 7<sup>th</sup> Edition. Philadelphia: W.B. Saunders Company. 2004:20-27.
69. Califf RM, Mark DB. Unstable angina: clinical presentation and diagnostic techniques. In Fuster V, Ross R, Topol EJ (eds): Atherosclerosis and Coronary Artery Disease, 2<sup>nd</sup> Edition. Philadelphia: Lippincott-Raven Press 2005:849-866.
70. Krucoff MW, Liebowitz R, Vogel JHK, Mark DB. Complementary and alternative therapies: opening the door to the science and practice of integrative medicine in cardiovascular care. In O'Rourke RA, Fuster V, Alexander RW (eds): The Heart Manual of Cardiology, 11<sup>th</sup> edition. New York: McGraw Hill. 2005:641-649.
71. Eisenstein EL, Mark DB. Cost effectiveness and new diagnostics and therapies for ACS. In: Topol EJ (ed): Acute Coronary Syndromes, 3<sup>rd</sup> Edition. New York: Marcel Dekker, Inc. 2004:723-746.
72. Mark DB. Screening tests. In: Gaziano J, Braunwald E (eds): Atlas of Cardiovascular Risk Factors. Philadelphia: Current Medicine, LLC. 2006:39-55.
73. Mark DB. Medical economics in cardiovascular medicine. In Topol EJ (ed): Textbook of Cardiovascular Medicine, 3<sup>rd</sup> Edition. Philadelphia: Lippincott Williams & Wilkins. 2006:736-756.
74. Mark DB. Medical economics for interventional cardiology. In Topol EJ (ed): Textbook of Interventional Cardiology, 5<sup>th</sup> Edition. Philadelphia: W.B. Saunders Company. 2008.
75. Mark DB. Decision-making in clinical medicine. In Braunwald E (ed): Harrison's Principles of Internal Medicine, 17<sup>th</sup> Edition. New York, NY: McGraw-Hill. 2008.
76. Krucoff MW, Costello R, Mark DB, Vogel JH. Complementary and alternative medical therapy in cardiovascular care. In O'Rourke RA, Fuster V, Alexander RW (eds): Hurst's the Heart Manual of Cardiology, 12<sup>th</sup> edition. New York: McGraw Hill. 2009:715-724.
77. Mark DB, Wong JB. Decision-making in clinical medicine. In Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J (ed): Harrison's Principles of Internal Medicine, 18<sup>th</sup> Edition. New York, NY: McGraw-Hill. 2012:19.
78. Krucoff MW, Costello R, Mark DB, Vogel JH. Complementary and alternative medical therapy in cardiovascular care. In O'Rourke RA, Fuster V, Alexander RW (eds): Hurst's the Heart Manual of Cardiology, 13<sup>th</sup> edition. New York: McGraw Hill. 2011:2429- 2440.

79. Mark DB. Economics and cost effectiveness in cardiology. In O'Rourke RA, Fuster V, Alexander RW (eds): Hurst's the Heart Manual of Cardiology, 13<sup>th</sup> edition. New York: McGraw Hill. 2011:2389-2408.
80. Mark DB. Medical economics for interventional cardiology. In Topol EJ, Tierstein PS (ed): Textbook of Interventional Cardiology, 6<sup>th</sup> Edition. Philadelphia: W.B. Saunders Company. 2012:861.
81. Mark DB, Wong JB. Decision-making in clinical medicine. In Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo (ed): Harrison's Principles of Internal Medicine, 19<sup>th</sup> Edition. New York, NY: McGraw-Hill. 2015:18-26.
82. Mark DB. Economics and cost effectiveness in cardiology. In Hurst's the Heart Manual of Cardiology, 14<sup>th</sup> edition. New York: McGraw Hill. In press.

#### **REVIEW ARTICLES (Not Peer Reviewed)**

1. Mark DB, Califf RM: Variant angina: Prognosis and therapy. Practical Cardiology 1986;12:25-38.
2. Bashore TM, Mark DB, Davidson C, Kisslo K, Skelton TN, Pryor DB. Iopamidol contrast use in the cardiac catheterization laboratory: initial experience in 1750 patients. Diagnostic Imaging Supplement 1987;9:19-22.
3. Mark DB, Hlatky MA, Pryor DB. Coronary obstructions: location with exercise electrocardiography. Cardiology Board Review 1987;4(7):90-99.
4. Bashore TM, Davidson CJ, Mark DB, Kisslo K, Hlatky MA, Skelton TN. Iopamidol use in the cardiac catheterization laboratory: A retrospective analysis of 3,316 patients. Cardio 1988;5(part 2):6-10.
5. Mark DB, Hlatky MA, Pryor DB. Using the exercise test to predict outcome in coronary artery disease. Cardiology Board Review 1988;5(2):163-171.
6. Mark DB, Hlatky MA, Pryor DB. Silent ischemia on the treadmill: What does it mean? Cardio 1989;6:99-104.
7. Pryor DB, DeLong E, Lipscomb J, Mark DB. Cost vs values: a model for incorporating value into clinical care. Group Practice J; May/June 1992;86-91.
8. Mark DB. Medical cost in interventional cardiology. Cardio 1993;3(3):13-16.
9. Mark DB. An overview of risk assessment in coronary artery disease. Am J Cardiol 1994; 73:19B-25B.

10. Califf RM, Mark DB. Percutaneous intervention, surgery and medical therapy: a perspective from the Duke Databank for Cardiovascular Diseases. *Seminars in Thoracic and Cardiovascular Surgery* 1994;6(2):120-128.
11. Mark DB. Risk stratification in patients with chest pain. In: Evans CH (ed): *Primary Care*. Philadelphia: W.B. Saunders Company. 1994;21(3):495-516.
12. Mark DB. Costs of interventional cardiac procedures. *J Intervent Card* 1994;7(4):369-378.
13. Hochrein J, Mark DB. CABG, PTCA, or medical management? Continuing evolution of therapy for coronary artery disease. *Primary Cardiology* 1995;21(8):21-26.
14. Mark DB. Clinical and economic lessons from studies of coronary thrombolysis. *JVIR* 1996; 6(6)Part 2:95S-101S.
15. Mark DB. Implications of cost in treatment selection for patients with coronary heart disease. *Ann Thorac Surg*, 1996;61:S12-15.
16. Mark DB. Analyse cout-efficacite du traitement thrombolytique avec l'activateur du plasminogene par rapport a la streptokinase dans l'infarctus aigu du myocarde. *Le Clinicien*, 1996;Supplement:13-16.
17. Mark DB. Economics and quality of life after acute myocardial infarction: insights from GUSTO I. *J of Throm and Thrombolysis* 1996;3:151-155.
18. Mark DB. Economics of heart failure treatment. *Am J Cardiol* 1997;80(8B):33H-38H.
19. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. *Am Heart J* 1998;135(6Pt 2Su):S285-92.
20. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Diagnosing and managing unstable angina. *Clinical Practice Guideline Number X*. AHCPR Publication No. 97-N010. December 1996.
21. Califf RM, Mark DB. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. *Am Heart J* 1997;134:S88-S96.
22. Mark DB, Peterson ED. Health economics of acute coronary syndromes. *J of Throm and Thrombolysis* 1998;5(S2):155-162.
23. Mark DB, Simons TA. Fundamentals of economic analysis. *Am Heart J* 1999;137(5):S38-S40.

24. Mark DB, Simons TA. Use of abciximab: comparative economic data. *Am Heart J* 1999;137(5):S123-S125.
25. Mark DB. When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial—an overview. *Can J Cardiol* 1998;14(SE):24E-27E.
26. Mark DB, Simons TA. Economic data in the phase II trial. *Am Heart J* 2000;139:S155-S157.
27. Califf RM, Stump D, Topol EJ, Mark DB. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. *Am Heart J* 1999;137:S90-S93.
28. Mark DB. Risk stratification in patients with chest pain. *Primary Care* 2001;28:99-118.
29. Prystowsky EN, Camm J, Lip G, Allessie M, Bergmann J, Breithardt G, Brugada J, Crijns H, Ellinor PT, Mark D, Naccarelli G, Packer D, Tamargo. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. *J Cardiovasc Electrophysiol* 2010;21(8):946-58.

## LETTERS

1. Harrell FE Jr., Lee KL, McKinnis RA, Hlatky MA, Mark DB, Califf RM, Pryor DB. Analysis of risk factors for sudden death after acute myocardial infarction [letter]. *Am J Cardiol* 1985;55:621-622.
2. Mark DB, Hlatky MA, Harrell FE Jr., Lee KL, Califf RM, Pryor DB. Reply: Treadmill score for predicting prognosis in coronary artery disease [letter]. *Ann Intern Med* 1987;107(4):595-596.
3. Mark DB, Douglas PS, Daniels MR. Economic outcomes with anatomical versus functional diagnostic testing for coronary artery disease. *Ann Intern Med* 2016;165(12):891.

## ABSTRACTS

Listing available upon request.

## SELECTED LECTURES



Economics of intervention: from randomized trials to daily practice. The Cleveland Clinic Foundation: The Practice of Cardiology: In the Midst of Health Care Reform Symposium. Atlanta, GA, March 12, 1994.

Psychosocial factors and prognosis in established CAD. Society of Behavioral Medicine 15th Annual Scientific Sessions: Symposium 2. Boston, MA, April 15, 1994.

The future of interventions in the era of managed care. Deaconess Hospital, Harvard Medical Center: Technical & Biological Aspects of Interventional Cardiology Conference. Boston, MA, April 29, 1994.

Review of the National Clinical Practice Guideline for Unstable Angina. Floyd Medical Center: Medical Grand Rounds. Rome, GA, May 4, 1994.

The cost of U.S. health care: perspectives gained from the GUSTO trial. Duke University Medical Center: 1994 Orgain Symposium: Clinical Trials Health Care Summit. Durham, NC, June 3, 1994.

Medical economics and cardiovascular disease. Duke University Medical Center: Medical Grand Rounds. Durham, NC, July 8, 1994.

Economic implications of innovations to improve the early management of acute MI. Florida Chapter, American College of Cardiology: Consensus Development Conference for Early Management of Acute Myocardial Ischemic Events in Florida. Tampa, FL, August 27, 1994.

Clinical outcome measures/cardiovascular databases. American College of Cardiology Board of Governors Meeting. Washington, DC, September 21, 1994.

Duke Databank experience with revascularization. Duke University Medical Center: Cardiac Anesthesiology Conference. Durham, NC, September 27, 1994.

Practice guidelines in cardiology: what does the future hold? CCS Satellite Symposium: Mega-Trials, Practice Guidelines and Economics: Impact on Clinical Practice. Edmonton, Alberta, October 29, 1994.

Anti-ischemic drugs for acute treatment and secondary prevention. American Heart Association's 67th Scientific Sessions: Plenary Session I. Dallas, TX, November 14, 1994.

Cost effectiveness of therapies for coronary artery disease. University of Texas Health Science Center: Internal Medicine Grand Rounds. Houston, TX, December 13, 1994.

Implications of cost in treatment selection for patients with CAD. Society of Thoracic Surgeons Annual Meeting: Risk Management in Coronary Artery Bypass Graft. Palm Springs, CA, January 28, 1995.

Outcomes research in cardiovascular medicine: the challenge of demonstrating value. St. Louis University Health Sciences Center: Internal Grand Rounds. St. Louis, MO, February 10, 1995.

Cost effectiveness of secondary prevention. Division of Cardiology at Duke University: Fourth Annual Cardiovascular Conference. Beaver Creek, CO, February 14, 1995.

What is a reasonable price for CABG and PTCA? A comparison over 50 centers. Division of Cardiology at Duke University: Fourth Annual Cardiovascular Conference. Beaver Creek, CO, February 15, 1995.

Risk stratification post MI should use: history, physical and functional testing. Division of Cardiology at Duke University: Fourth Annual Cardiovascular Conference. Beaver Creek, CO, February 15, 1995.

Cardiovascular financial implications--health care reform. Mercy Heart Institute: Hidden Valley Two Day Conference. Hidden Valley, PA, February 26, 1995.

Economic substudy in GUSTO II. Ciba Workshop on Economic Evaluation. Freiburg, Germany, March 29, 1995.

Clinical lessons from coronary thrombolysis studies: major trials, their results, and relevance to noncoronary thrombolytic therapy. Summit Meeting: Thrombolytic Therapy in Peripheral Vascular Disease. Snowbird, UT, April 9, 1995.

Cost effectiveness considerations in coronary thrombolysis. Summit Meeting: Thrombolytic Therapy in Peripheral Vascular Disease. Snowbird, UT, April 9, 1995.

The economics of chronic cardiovascular disease. Duke University Clinical Cardiovascular Studies 14th Annual Edward S. Orgain Cardiovascular Symposium: Cost Effective Therapy Symposium. Durham, NC, May 6, 1995.

Practice guidelines and other regulatory aspects. St. John Hospital and Medical Center: Frontiers in Cardiology, 1995. Detroit, MI, May 24, 1995.

The GUSTO EQOL study--cost effectiveness of thrombolytic therapy with tissue plasminogen activator versus streptokinase for acute myocardial infarction. Notre-Dame Hospital and the Montreal Heart Institute: Mega-Trials, Provincial Practice Guidelines and Pharmacoeconomics: Their Impact on Clinical Practice. Montreal, Quebec, June 9, 1995.

Cost efficient management of MI's and unstable angina: an oxymoron? Division of Cardiology at Duke University: War Against Atherosclerosis IV: Management of Acute Coronary Syndromes. Durham, NC, June 17, 1995.

Should outcomes research dictate practice guidelines? American Heart Association, Greater Los Angeles Affiliate: Current Controversies in Cardiology. 63rd Annual Fall Symposium, Los Angeles, CA, September 13, 1995.

The EQOL study: Economic and quality of life evaluations from the GUSTO Trial. St. Michael's Hospital, Division of Cardiology. Issues in the Management of Acute Myocardial Infarction: A Framework for Canadian Clinical Practice. Toronto, Ontario, September 20, 1995.

Cost effectiveness of thrombolytics in myocardial infarction. University of Ottawa Heart Institute, Grand Rounds. Ottawa, Ontario, September 21, 1995.

Cost effectiveness of thrombolytics in myocardial infarction. Ottawa General Hospital, Grand Rounds. Ottawa, Ontario, September 21, 1995.

Outcomes: how to choose and how to measure. Duke Heart Center: 2nd Annual Shaping the Future Multidisciplinary cardiovascular conference. Durham, NC, September 22, 1995.

Should fewer cardiologists and cardiac surgeons do more coronary interventional procedures? What the volume-outcome studies tell us. American College of Cardiology: Enhancing Quality and Value in Cardiovascular Care. Keystone, CO, September 28, 1995.

Resource use and quality of life after acute myocardial infarction in the U.S. and Canada. American College of Cardiology: Enhancing Quality and Value in Cardiovascular Care. Keystone, CO, September 30, 1995

An overview of risk assessment in coronary artery disease. Sierra Heart Institute: Trends in Cardiovascular Medicine: Cardiology for the Primary Physician. Olympic Valley, CA, October 1, 1995.

Ischemic heart disease: which patients should undergo cardiac catheterization and how should they be treated post-catheterization? Sierra Heart Institute: Trends in Cardiovascular Medicine: Cardiology for the Primary Physician. Olympic Valley, CA, October 1, 1995.

Economics and quality of life after AMI: insights from GUSTO. University of Alberta: Towards 2000: New Pathways for the Clinical Management of Acute Ischemic Syndromes. Toronto, Ontario, October 24, 1995.

History, physiology, and stress ECG--is imaging always necessary? American Heart Association 68th Scientific Sessions: Plenary Session XI. Anaheim, CA, November 16, 1995.

Economics and secondary prevention. Division of Cardiology at Duke University: Fifth Annual Cardiovascular Conference. Beaver Creek, CO, February 11, 1996.

Outcomes research using large clinical databases. North Carolina Chapter of the College of Physicians: Annual Meeting. Durham, NC, February 16, 1996.

Diagnosis and therapeutic strategies following thrombolytic therapy for acute myocardial infarction. Southwest Washington Medical Center: Cardiology Section. Vancouver, WA, February 26, 1996.

Reperfusion therapy and care of the acute MI patient: where do we stand? Portland Adventist Medical Center: Cardiology Grand Rounds. Portland, OR, February 27, 1996.

PTCA: are we too aggressive? Interventional Cardiology XXX: Emory University School of Medicine. Orlando, FL, March 22, 1996.

Cost and efficacy issues. Myocardial Reperfusion and Acute Coronary Syndromes: GUSTO II and Beyond: Ninth Annual Meeting. Orlando, FL, March 23, 1996.

PTCA versus thrombolysis for acute myocardial infarction: cost effectiveness of each treatment strategy. American College of Cardiology: 45th Annual Scientific Sessions, Symposium 619. Orlando, FL, March 27, 1996.

Establishment, implementation, and monitoring: guideline development and outcomes measurement for cardiology/cardiovascular surgery. Cardiovascular/Thoracic Surgery and Cardiology Assembly. Marco Island, FL, April 16, 1996.

Economics of coronary revascularization: an update. Grand Rounds: Cleveland Clinic. Cleveland, OH, April 19, 1996.

Cost effectiveness of reperfusion strategies: insights from GUSTO I & II. Cardiology 1996: Prevention and Management of Coronary Disease: Baystate Medical University. Springfield, MA, April 26 1996.

The role of outcome-based research on ICD Practice. ICDs in 1996: Patient Access to Therapy, Indications and Guidelines for Use: NASPE/ACC State-of-the-Art Conference. Seattle, WA, May 14, 1996.

In-hospital treatment of uncomplicated MI. Cardiology Grand Rounds: Meridian Park Hospital. Portland, OR, May 15, 1996.

How to reduce the cost of managing heart failure. Frontiers in Cardiology 1996: Northwestern University Medical School. Chicago, IL, June 8, 1996.

How to find a job/build a career in academic medicine. How to Become a Clinical Cardiovascular Investigator: American Heart Association Council on Clinical Cardiology and the American College of Cardiology. Bethesda, MD, June 13, 1996.

Resource use and quality of life after acute myocardial infarction. Cardiovascular Disease: State of the Art, 1996: Lahey Hitchcock Clinic. Brewster, MA, June 26, 1996.

Observational databases. The Yellowstone Summit on Cardiology Practice: Preserving Quality in an Era of Cost Restraint: American College of Cardiology. West Yellowstone, MT, July 30, 1996.

Acute MI: streptokinase or t-PA? The Yellowstone Summit on Cardiology Practice: Preserving Quality in an Era of Cost Restraint: American College of Cardiology. West Yellowstone, MT, July 30, 1996.

In pursuit of best practice: outcomes management. Duke Heart Center Multidisciplinary Cardiovascular Conference: Duke University Medical Center, Durham, NC, September 19, 1996.

Exercise testing: value in predicting outcomes. American Association of Cardiovascular and Pulmonary Rehabilitation Annual Conference; Baltimore, MD, September 20, 1996.

Health care economics in acute coronary syndromes: what constitutes cost effective therapy in 1996? Towards 2000-New Strategies for Acute Coronary Syndromes: University of Alberta, Edmonton. Montreal, ON, October 29, 1996.

Update on economics in interventional cardiology. INTERVENT '97: The Cleveland Clinic, Cleveland, OH. New Orleans, LA, November 9, 1996.

The stent explosion: the financial fallout. American Heart Association 69th Scientific Sessions: Plenary Session X. New Orleans, LA, November 13, 1996.

Economic evaluation of the GUSTO study. Cost-Effectiveness Analysis: Measures and Methods in Clinical Trials: Drug Information Association. New Orleans, LA, November 15, 1996.

The role of economic analysis in assessing cardiovascular treatment options. Current Focus in Treating and Managing Coronary Heart Disease and Heart Failure. Ft. Lauderdale, FL, January 16, 1997.

Financial implications of coronary stenting and other interventional procedures. Challenges in Interventional Cardiology: Institute for Continuing Healthcare Education. Durham, NC, January 30, 1997.

U.S. trends and outcomes in CHF therapy. Division of Cardiology at Duke University: Fifth Annual Cardiovascular Conference. Beaver Creek, CO, February 9, 1997.

What is outcomes research? Department of Medicine, Duke University, Department of Medicine Research Conference. Durham, NC, February 24, 1997.

Economics of reperfusion strategies. The University of Vermont: Tutorial in Cardiology. Sugarbush, VT, February 26, 1997.

Differences in treatment outcomes, quality of life, and costs of care for acute myocardial infarction between the US and Canada. The University of Vermont: Tutorial in Cardiology. Sugarbush, VT, February 27, 1997.

When do innovative therapies make economic sense? Lessons from ESSENCE. International Cardiology Forum: Revisiting the standard of care: The emerging role of low-molecular-weight heparins in cardiology practice. Anaheim, CA, March 15, 1997.

Critical pathways for inpatient management: Do they work? American College of Cardiology 46th Annual Scientific Sessions: Health Care Reform: Update '97. Anaheim, CA, March 17, 1997.

Assessing value and quality in cardiovascular care. University of Virginia, Cardiology Grand Rounds. Charlottesville, VA, April 15, 1997.

The role of outcomes-based trials. NASPE Annual Meeting. New Orleans, LA, May 7, 1997.

Cost effectiveness of exercise testing. Boston University Medical Center, Cardiology Grand Rounds. Boston, MA, May 12, 1997.

Cost effectiveness and quality of life: the patient's perspective. American Heart Association Maryland Affiliate: Brain Attack: Implications for Stroke Care in Maryland. Baltimore, MD, June 6, 1997.

Economic and quality of life issues in coronary revascularization—insights from recent clinical trials. University of South Carolina School of Medicine: Cardiovascular Disease in the Year 2000. Columbia, SC, June 7, 1997.

When do innovative therapies make economic sense? McMaster University School of Medicine: Low Molecular Weight Heparins: New Horizons in Cardiovascular Disease. Montreal, June 28, 1997.

Through the Looking Glass: Hippocrates in managed-care land. Medicine Grand Rounds: Duke University Medical Center. Durham, NC, August 15, 1997.

Acute ischemic coronary syndromes—quantifying the cost. Acute Ischemic Coronary Syndromes—Assessing Disease Burden and Impact: European Society of Cardiology. Stockholm, Sweden, August 24, 1997.

Pharmacoeconomic issues in the management of heart failure. Scientific Meeting: Heart Failure Society of America. Baltimore, MD, September 23, 1997.

Healthcare economic realities: industry/hospitals/practitioners and the patient. Towards 2000: New Pathways in the Management of Acute Coronary Syndromes III. CCS Satellite Symposium: University of Alberta. Winnipeg, Manitoba, October 5, 1997.

Healthcare economics: what constitutes cost effective therapy? Towards the New Millennium: Understanding Issues in Myocardial Reperfusion. CCS Satellite Symposium. Winnipeg, Manitoba, October 5, 1997.

Cost effectiveness: how we define the problem? Cost Effectiveness of Coronary Intervention: AHA Satellite Symposium: University of Texas. Orlando, FL, November 9, 1997.

Optimizing outcomes: the socio-economic perspective. Discovery: The Emerging Role of Low-Molecular-Weight Heparins in Acute Coronary Syndromes. AHA Satellite Symposium. Orlando, FL, November 9, 1997.

Efficacy and cost effectiveness of catheter-based coronary revascularization vs. CABG: which approach is best? Aggressive vs. Conservative Management of Coronary Syndromes: Clinical Outcomes and Cost-Effectiveness. SUNY Health Science Center. AHA Satellite Symposium. Orlando, FL, November 9, 1997.

The economics of intervention in the ACS. Managing Acute Coronary Syndromes: Current Controversies. Duke University Medical Center: AHA Satellite Symposium. Orlando, FL, November 11, 1997.

Collaborative management of the patient: the cardiologist's view. New Era Cardiac Care: Minimally Invasive Techniques. Cardiothoracic Research and Education Foundation. Palm Springs, CA, January 11, 1998.

Economics of glycoprotein IIb/IIIa inhibitors. Cardiology Grand Rounds: Beth Israel Deaconess Hospital. Boston, MA, January 29, 1998.

Should we look for silent ischemia? Division of Cardiology at Duke University: Seventh Annual Cardiovascular Conference. Beaver Creek, CO, February 9, 1998.

Cost effectiveness analysis: cents or nonsense? Emory University School of Medicine: Research Conference. Atlanta, GA, March 6, 1998.

Evaluating pharmacoeconomics and improving guidelines: a practical approach. The Dawn of a New Era in the Management of Acute Ischemic Syndromes: The Second Annual ACC Symposium: The Cleveland Clinic Foundation. Atlanta, GA, March 28, 1998

Optimizing outcomes: the socioeconomic perspective. Discovery: The Emerging Role of Low-Molecular Weight Heparins in Acute Coronary Syndromes. Cardiovascular Institute of Loyola University Medical Center. Atlanta, GA, March 28, 1998.

Electrocardiographic testing: cheap, effective. American College of Cardiology 47th Annual Scientific Sessions: Cost-Effective Diagnostic Testing in Suspected Coronary Artery Disease. Atlanta, GA, March 29, 1998

Cost effectiveness issues. American College of Cardiology 47th Annual Scientific Sessions: Rethinking Revascularization: Conservative Therapy of Coronary Artery Disease. Atlanta, GA, March 31, 1998

Medical vs. revascularization therapy for patients with coronary artery disease. Cardiology Grand Rounds, University of Texas Health Science Center. San Antonio, TX, April 14, 1998.

Optimizing outcomes: the socioeconomic perspective. Advances in Unstable Angina: The Role of Low-Molecular Weight Heparins. World Congress of Cardiology, Rio de Janeiro, April 27, 1998.

Sudden cardiac death in heart failure: the SCD-HeFT trial. Electrophysiology Research Conference, The Sanger Clinic, Charlotte, NC, May 14, 1998.

Cost effectiveness: the US perspective. The Yellowstone Summit on Cardiology Practice: Proving and Improving Performance in a Changing Environment: American College of Cardiology. West Yellowstone, MT, August 2, 1998.

Acute MI cost effective lysis. The Yellowstone Summit on Cardiology Practice: Proving and Improving Performance in a Changing Environment. West Yellowstone, MT, August 3, 1998.

The PURSUIT economic substudy: the US perspective. A cost-effective approach to the management of acute ischaemic coronary syndromes—A Satellite Symposium to the European Society of Cardiology Meetings. Vienna, Austria, August 25, 1998.

Advances in the treatment of acute coronary syndromes. Meeting of the Houston Cardiology Society and Cardiovascular Nursing Society. Houston, TX, September 17, 1998.

Establishing cost/benefit/value in managing acute coronary syndromes. Toward 2000 IV: New Concepts in the Management of Acute Coronary Syndromes. CCS Satellite Symposium: University of Alberta. Ottawa, Ontario, October 20, 1998.



The economic burden of acute coronary syndromes. From Acute Care to Secondary Prevention of ACS: A Focus on GP IIb/IIIa Antagonism. Duke University Medical Center. Dallas, TX, November 7, 1998.

How do I sum this up for clinical practice? American Heart Association Council on Clinical Cardiology. Dallas, TX, November 8, 1998.

Predicting and promoting myocardial viability: the impact of managed care—dollars and sense. American Heart Association, Plenary Session VII. Dallas, TX, November 10, 1998.

Analysis of cost effectiveness in clinical trials. TNF $\alpha$  Blockade: A New Frontier in Rheumatology. Duke University Medical Center. San Diego, CA, November 12, 1998.

Evolving trends in the management of ACS and AMI. Cardiology Grand Rounds: Deborah Heart and Lung Center. Browns Mills, NJ, December 3, 1998.

How effectively are clinicians treating CHF in the US today? Division of cardiology at Duke University: Eighth Annual Cardiovascular Conference. Beaver Creek, CO, February 8, 1999.

Stress electrocardiogram: does it still have a role? Noninvasive testing for coronary artery disease: which test to use and when?: American College of Cardiology 48th Annual Scientific Session. New Orleans, LA, March 7, 1999.

New anticoagulants and antithrombotics agents in cardiology/economic impact. Contemporary approaches to anticoagulation disorders symposium. Dearborn, MI, March 24, 1999.

Challenges in selecting outcomes measures. American Heart Association Scientific Forum on Cardiovascular Disease and Stroke Quality of Care and Outcomes Research. San Diego, CA, May 24, 1999.

Advances in the pharmacotherapy of acute coronary syndromes: clinical and economic issues. Patient management and economics of acute coronary syndromes conference. American Society of Health System Pharmacists annual meeting. Reno, NV, June 7, 1999.

Cost/efficacy analysis—GPIIb/IIIa antagonists in unstable angina/non-Q wave myocardial infarction. The era of GPIIb/IIIa antagonists international workshop. Lake Como, Italy, June 17, 1999.

Stress electrocardiogram: does it still have a role? IX Congreso Puertorriqueno de Cardiología. San Juan, Puerto Rico, July 18, 1999.

Economics of acute coronary syndromes. Acute coronary syndromes conference. University of Maryland, College Park, MD, August 7, 1999.

Should I publish your work? Pointers from a medical journal editor's perspective. Write the right way: learning the skills necessary to write and publish your scientific and clinical medical results symposium. Intermountain Health Care. Salt Lake City, Utah, August 13, 1999.

Challenges in selecting outcomes measures. 20th annual cardiovascular symposium. Saint Vincent Health Center. Erie, PA, September 17, 1999.

Cost/efficacy analysis of GPIIb/IIIa antagonists in unstable angina/non-Q wave myocardial infarction. Current problems in cardiology 1999: diagnostic and therapeutic challenges for cardiologists and primary care physicians. Deborah Heart Center. Browns Mills, NJ, October 9, 1999.

Choosing the right test for the right patient at the right time. Reducing mortality from coronary artery disease: choosing the right test for the right patient at the right time. Cotton O'Neil Heart Center. Topeka, KS, October 15, 1999.

Exercise electrocardiography. American Heart Association cardiovascular seminar #65, AHA 72nd Scientific Sessions. Atlanta, GA, November 8, 1999.

Is there value to stenting coronaries and/or using IIb/IIIa inhibitors? Oklahoma Heart Institute. Tulsa, Oklahoma, May 5, 2000.

ICD cost-effectiveness results and potential impact on ICD utilization. Global variations in ICD use. Too high? Too low? Just right? Washington, DC, May 19, 2000.

Cost-effective strategies should have priority. Cardiovascular health in developing countries. 21st Sao Paulo Cardiology Society Congress. Campos do Jordao, Brazil, May 26, 2000.

Therapeutic approach based on cost-effectiveness. Acute coronary syndromes: new paradigms optimizing the results. 21st Sao Paulo Cardiology Society Congress. Campos do Jordao, Brazil, May 26, 2000.

Economic analysis in cardiology: an essential component for the clinical decision. 21st Sao Paulo Cardiology Society Congress. Campos do Jordao, Brazil, May 27, 2000.

Clinical trials - the good, the bad, the ugly. John N. Wilson, MD, lectureship in cardiovascular diseases - cardiology update 2000. Presbyterian Healthcare Services. Albuquerque, NM, October 6, 2000.

Point/counterpoint: is the cardiovascular physical exam dead or dying? John N. Wilson, MD, lectureship in cardiovascular diseases - cardiology update 2000. Presbyterian Healthcare Services. Albuquerque, NM, October 6, 2000.

Medication errors: a multifactorial issue. 7th Annual Duke Heart Center Conference. Durham, NC, October 13, 2000.

Pharmacoeconomics of LMWH, 2B/3As, stents. Treatment of unstable angina/Non-ST segment elevation myocardial infarction. American Heart Association 73rd Scientific Sessions. New Orleans, LA, November 12, 2000.

Economic analysis. Preceptorship for advanced cardiovascular education. Duke Clinical Research Institute. Durham, NC, December 4, 2000.

Outcomes measures. Scientific conference on therapeutic angiogenesis and myocardial laser revascularization. Santa Fe, NM, January 27, 2001.

Role of electrocardiogram and clinical variables. American College of Cardiology 50th Annual Scientific Session. Orlando, FL, March 20, 2001.

Drug approval and randomized clinical trials. Biotechnology and the genetics revolution. Fuqua School of Business. Durham, NC, April 2, 2001.

Cardiovascular disease: trends in health care costs and benefits. The National Academy of Sciences. Washington, DC, June 14, 2001.

New prognostic markers from the ECG. American Heart Association 74th Scientific Sessions. Anaheim, CA, November 12, 2001.

Cardiovascular burden of disease: the need for streamlined approaches. American Heart Association 74th Scientific Sessions. Anaheim, CA, November 12, 2001.

Drug approval and randomized clinical trials. Biotechnology and the genetics revolution. Fuqua School of Business. Durham, NC, March 25, 2002.

Cost effectiveness of heart failure therapy. Heart failure in older adults: from efficacy to effectiveness. American Geriatric Society. Washington, DC, May 12, 2002.

Medical economics. International Cardiology Forum 5<sup>th</sup> Annual International Experts Meeting. Cannes, France, October 4, 2002.

Clinical trial design and the FDA approval process. Ochsner Clinic Foundation. New Orleans, LA, October 9, 2002.

Current management of AMI: evidence for combination therapy and facilitated PCI. Ochsner Clinic Foundation. New Orleans, LA, October 9, 2002.

Applying clinical trial data to individuals. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference. Washington, DC, October 13, 2002.

How should cost effectiveness impact on difficult choices? New concepts in acute coronary syndromes: beyond 2000 (VIII). Canadian Cardiovascular Society. Edmonton, Alberta, Canada, October 27, 2002.

Cost issues and prevention. American Heart Association 75th Scientific Sessions. Anaheim, CA, November 17, 2002.

The economics of drug-eluting stents. Drug-eluting stents: separating the wheat from the chaff. Baylor Medical College symposium. Chicago, IL, November 19, 2002.

How to evaluate the cost effectiveness of cardiovascular treatments. Belgian Society of Cardiology. Brussels, Belgium, January 30, 2003.

Should socio-economic status impact on the design, results, and interpretation of clinical trials? Socio-economic status and cardiac care: from bedside to policy. Toronto, Ontario, Canada, February 10, 2003.

Drug approval and randomized clinical trials. Biotechnology and the genetics revolution. Fuqua School of Business. Durham, NC, March 24, 2003.

Is atherosclerosis imaging cost effective? American College of Cardiology 52nd Annual Scientific Session. Chicago, IL, April 1, 2003.

Who is going to pay for coated stents, ICDs, and biventricular pacers? Economic impact on new technology: who is going to pay for all this? Virginia Chapter of the American College of Cardiology Annual Meeting. Charlottesville, VA, April 25, 2003.

Towards economically rational management of ACS. 6<sup>th</sup> International Experts' Meeting of the International Cardiology Forum. Lisbon, Portugal, October 9, 2003.

Economic impact of new technology. Heart failure: a revolution in treatment. American Heart Association 76th Scientific Sessions. Orlando, FL, November 9, 2003.

Will it break the bank? Has the drug-eluting stent revolution arrived? American Heart Association 76th Scientific Sessions. Orlando, FL, November 9, 2003.

Careers in clinical cardiovascular research. How to become a cardiovascular investigator. ACC/AHA/NHLBI conference. Bethesda, MD, November 22, 2003.

Drug approval and randomized clinical trials. Biotechnology and the genetics revolution. Fuqua School of Business. Durham, NC, March 30, 2004.

The evolution of heart failure management and new interpretations from the landmark SCD-HeFT trial on effectively managing these patients. Hermann Memorial Medical Center Grand Rounds. Houston, TX, April 29, 2004.

How will the advances in heart failure therapy affect my patients? Brennan's. Houston, TX, April 29, 2004.

Careers in clinical cardiovascular research. How to become a cardiovascular investigator. ACC/AHA/NHLBI conference. Bethesda, MD, May 15, 2004.

Sudden Cardiac Death in Heart Failure: what do we do after SCD-HeFT? can all this possibly be cost effective? Moscone Convention Center. San Francisco, CA, May 19, 2004.

Cost effective use of imaging. Society of Atherosclerosis Imaging Third International Meeting. New Orleans, LA, May 23, 2004.

Drug eluting stents and defibrillators: will they save the day or sink the ship? University of Alberta Grand Rounds. Edmonton, Alberta, Canada. June 4, 2004.

Incorporating cost effectiveness into cardiovascular trials. Annual Scientific Meeting of Cardiac Society of Australia and New Zealand 2004. Brisbane, Australia. August 8, 2004.

Cost effectiveness and device therapy. Annual Scientific Meeting of Cardiac Society of Australia and New Zealand 2004. Brisbane, Australia. August 8, 2004.

ICDs in heart failure: Is cost containment possible? Annual Scientific Meeting of Cardiac Society of Australia and New Zealand 2004. Brisbane, Australia. August 9, 2004.

Cost benefits of heart failure management. Annual Scientific Meeting of Cardiac Society of Australia and New Zealand 2004. Brisbane, Australia. August 10, 2004.

Drug eluting stents: can the cost be justified?. Annual Scientific Meeting of Cardiac Society of Australia and New Zealand 2004. Brisbane, Australia. August 10, 2004.

Pacing in heart failure: cost effectiveness in relation to other therapies. Annual Scientific Meeting of Cardiac Society of Australia and New Zealand 2004. Brisbane, Australia. August 10, 2004.

Healthcare economics in ACS: art, science, or metaphysics? New Concepts in Acute Coronary Syndromes: Beyond 2000 (X). Canadian Cardiovascular Society Annual General Meeting. Calgary, Alberta, October 24, 2004.

Cost effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Association 77th Scientific Sessions. New Orleans, Louisiana, November 10, 2004.

ICD therapy. Duke University Medical Center, Grand Rounds. Durham, North Carolina. January 10, 2005.

Drug eluting stents and defibrillators: will they save the day or sink the ship? Rising cost of cardiac healthcare. Grand Rounds, Mt. Sinai. New York City, New York. April 18, 2005.

Antagonist. Controversies in devices: cardiac resynchronization is cost effective for patients with moderately severe heart failure. Heart Rhythm 2005: 26<sup>th</sup> Annual Scientific Sessions. New Orleans, LA. May 5, 2005.

Can we afford CRT therapy: socioeconomic analysis of CRT. Mending broken hearts-managing the rhythm of life: mechanical rhythm of the heart. Heart Rhythm 2005: 26<sup>th</sup> Annual Scientific Sessions. New Orleans, LA. May 7, 2005.

Economic implications of implantable cardioverter defibrillators. Prevention of Sudden Cardiac Death: Selecting Patients and Implementing Therapy. American College of Cardiology 55th Annual Scientific Session. Atlanta, GA, March 13, 2006.

Practice guidelines: medical legal considerations. Medical Malpractice in Cardiovascular Medicine. American College of Cardiology 55th Annual Scientific Session. Atlanta, GA, March 14, 2006.

How to evaluate the cost effectiveness of our therapies in 2006. 15<sup>th</sup> Interventional Cardiology Symposium. Montreal, Canada. June 16, 2006.

Making tough cost effectiveness choices. VIGOUR Symposium. A satellite symposium of the ESC Congress 2006. Barcelona, Spain. September 4, 2006.

Managing rising cost/cost effectiveness. Chair. ESC Congress 2006. Barcelona, Spain. September 5, 2006.

Economic issues in cardiovascular prevention with drugs. ESC Congress 2006. Barcelona, Spain. September 5, 2006.

Cost effectiveness of cardiac tests and therapies. Grand Rounds. Saint Vincent Hospital. Indianapolis, Indiana. November 30, 2006.

Interpreting randomized clinical trials. Richter Symposium Lecture. Saint Vincent Hospital. Indianapolis, Indiana. December 1, 2006.

High-dose atorvastatin- better value for money: the Treating to New Targets trial US economic substudy in 5308 stable coronary heart disease patients. American College of Cardiology 56th Annual Scientific Session. New Orleans, LA. March 26, 2007.

How to get your paper published. American College of Cardiology 56th Annual Scientific Session. New Orleans, LA. March 26, 2007.

Cost effectiveness and efficiency of AFib ablation: can we afford next year's non-pharmacologic treatment of AFib? Hearst Rhythm 2007. Denver, CO. May 10, 2007.

Why does the ACC/AHA like standard treadmill testing for evaluation of chest pain? The Alabama Chapter of the American College of Cardiology, 16<sup>th</sup> annual meeting. Destin, FL. June 2, 2007.

PCI in the OAT trial: lots of bucks, not much bang. American Heart Association Scientific Sessions 2007. Orlando, FL. November 5, 2007.

The economics of interventional cardiology. Emory Practical Intervention Course (EPIC 2008). Atlanta, GA. April 26, 2008.

How to discuss the risks and benefits of ICD and BiV pacers with patients: the risks and benefits for primary prevention. American Heart Association Scientific Sessions 2008. New Orleans, LA. November 9, 2008.

Quality of life outcomes with surgical ventricular reconstruction in symptomatic heart failure: results from the STICH trial. American College of Cardiology 2009 Annual Scientific Session. Orlando, FL. March 31, 2009.

Can we afford to use mechanical devices for heart failure? Heart Failure Society of America 14<sup>th</sup> Annual Scientific Meeting. San Diego, CA. September 14, 2010.

Yoga, Heart Health and Disease. Mountain Pose Yoga Festival 2011. Copper Mountain, CO. July 10, 2011.

Late Breaking: Quality of life outcomes in the STICH trial. Heart Failure Society of America 15<sup>th</sup> Annual Scientific Meeting. Boston, MA. September 19, 2011.

Art of Medicine: a modern reinterpretation. Duke University Medical Center Cardiology Grand Rounds. Durham, NC. October 18, 2011.

Art of Medicine: a modern reinterpretation. Columbia University Grand Rounds. New York, NY. December 6, 2011.

Art of Medicine: a modern reinterpretation. University of Alberta Cardiology Divisional Rounds. Edmonton, Alberta, Canada. January 18, 2012.

Understanding What Works in Medicine: common myths and misconceptions. University of Alberta research seminar. Edmonton, Alberta, Canada. January 18, 2012.

Art of Medicine: a modern reinterpretation. New York University Grand Rounds. New York, NY. March 6, 2012.

Late Breaking: Quality of life outcomes in the Trial to Assess Chelation Therapy. American Heart Association Scientific Sessions 2012. Los Angeles, CA. November 4, 2012.

Medical Research Journals: Editor's Insights. Cardiology Grand Rounds. Duke University School of Medicine. Durham, NC. February 12, 2013

The Trial to Assess Chelation Therapy: The Story Behind the Headlines. Duke Clinical Research Institute Research Conference. Durham, NC. April 9, 2013.

Understanding What Works in Medicine: Translating Evidence into Practice. Duke Biostatistics & Bioinformatics Department Seminar. Durham, NC. September 20, 2013.

Understanding What Works in Medicine: The Role of the RCT. DCRI Fellows Seminar Series. Durham, NC. March 10, 2014.

DAPT Trial DES vs BMS Comparison: Commentary. American Heart Association Scientific Sessions 2014. Chicago, IL. November 18, 2014.

Editor's Roundtable. Cardiology Grand Rounds. Duke University School of Medicine. Durham, NC. February 3, 2015.

The PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial: Economic Outcomes. American College of Cardiology Scientific Sessions 2015. San Diego, CA. March 15, 2015.

Understanding What Works in Medicine: The Role of the RCT Part 1. DCRI Fellows Lecture Series. Durham, NC. April 6, 2015.

Understanding What Works in Medicine: The Role of the RCT Part 2. DCRI Fellows Lecture Series. Durham, NC. April 13, 2015.

Evolution of Patient Reported Outcome Measures (PROMs): There and Back Again. American Heart Association Scientific Sessions 2015. Orlando, FL. November 9, 2015.

Understanding What Works in Medicine: Translating Evidence to Practice. University of Virginia Grand Rounds/Crampton Lecture. Charlottesville, VA. November 30, 2015.

25 Years of Studying Cost Effectiveness: What Have We Learned? Beaver Creek 25<sup>th</sup> Annual Cardiovascular Conference. Avon, Colorado. February 7, 2016.



Chelation Therapy for Coronary Artery Disease. Beaver Creek 25<sup>th</sup> Annual Cardiovascular Conference. Avon, Colorado. February 8, 2016.

Understanding What Works in Medicine: The Role of the RCT Part 1. DCRI Fellows Lecture Series. Durham, NC. March 7, 2016.

Understanding What Works in Medicine: The Role of the RCT Part 2. DCRI Fellows Lecture Series. Durham, NC. April 27, 2016.

ACC Value Framework. ISPOR Value Stakeholder Conference on Value Assessment Frameworks. Washington, DC. September 23, 2016.

Understanding What Works in Medicine: Translating Evidence to Practice. Mount Sinai Medical Center, Cardiovascular Grand Rounds. Miami Beach, FL. January 12, 2017.

Value-Based Payment: A Look Behind the Curtain. Beaver Creek 26<sup>th</sup> Annual Cardiovascular Conference. Avon, Colorado. February 5, 2017.

5 Habits of Successful Clinical Researchers. DCRI Research Training Camp. Durham, NC. April 8, 2017.

Clinical Perspectives on Recovery from MI. Keeping the Heart Young: Cardiovascular Robustness, Resilience, and Rejuvenation. Durham, NC. July 18, 2017.

ICD – The Success Story. Cardiomyopathy, Sudden Cardiac Death and ICD. European Society of Cardiology Congress 2017. Barcelona, Spain. August 27, 2017.

Chair. Imaging to Identify Patients at Risk of Arrhythmia. European Society of Cardiology Congress 2017. Barcelona, Spain. August 27, 2017.

PCSK9 Inhibitors: Breakthrough in LDL Lowering or Breakdown in Value? 27<sup>th</sup> Annual Cardiovascular Conference. Beaver Creek, CO. February 11, 2018.

Pass the Olive Oil or Pass the Butter? Is Food Epidemiology Hopeless? 27<sup>th</sup> Annual Cardiovascular Conference. Beaver Creek, CO. February 14, 2018.

Cost Effectiveness of NOACs for Patients with Atrial Fibrillation: Are They Worth It? Treating patients with atrial fibrillation symposium. Chapel Hill, NC. February 26, 2018.